US20040198712A1 - Method for labeling phosphorylated peptides, method for selectively adsorbing phosphorylated peptides, complex compounds used in the methods, process for producing the complex compounds, and raw material compounds for the complex compounds - Google Patents
Method for labeling phosphorylated peptides, method for selectively adsorbing phosphorylated peptides, complex compounds used in the methods, process for producing the complex compounds, and raw material compounds for the complex compounds Download PDFInfo
- Publication number
- US20040198712A1 US20040198712A1 US10/784,576 US78457604A US2004198712A1 US 20040198712 A1 US20040198712 A1 US 20040198712A1 US 78457604 A US78457604 A US 78457604A US 2004198712 A1 US2004198712 A1 US 2004198712A1
- Authority
- US
- United States
- Prior art keywords
- compound
- group
- complex
- mmol
- pyridylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 170
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 title claims abstract description 57
- 238000002372 labelling Methods 0.000 title claims abstract description 40
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 19
- 230000008569 process Effects 0.000 title description 17
- 239000002994 raw material Chemical class 0.000 title description 9
- 125000005647 linker group Chemical group 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims description 64
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 44
- 235000020958 biotin Nutrition 0.000 claims description 18
- 239000011616 biotin Substances 0.000 claims description 18
- 229960002685 biotin Drugs 0.000 claims description 18
- 125000003277 amino group Chemical group 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 102000004169 proteins and genes Human genes 0.000 abstract description 14
- 239000000243 solution Substances 0.000 description 69
- 239000000203 mixture Substances 0.000 description 43
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 239000011701 zinc Substances 0.000 description 30
- 239000000499 gel Substances 0.000 description 29
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 28
- 229910052725 zinc Inorganic materials 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 27
- 0 C1=CC=N2C(=C1)C[N@]13CC4=CC=CC=N4[Zn+2]21O1C(C[N@]24CC5=N(C=CC=C5)[Zn+]12N1=C(C=CC=C1)C4)C3.CC[Y] Chemical compound C1=CC=N2C(=C1)C[N@]13CC4=CC=CC=N4[Zn+2]21O1C(C[N@]24CC5=N(C=CC=C5)[Zn+]12N1=C(C=CC=C1)C4)C3.CC[Y] 0.000 description 26
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 25
- 238000005160 1H NMR spectroscopy Methods 0.000 description 23
- 238000001914 filtration Methods 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 18
- 238000000926 separation method Methods 0.000 description 18
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 17
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 17
- 238000010898 silica gel chromatography Methods 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000012043 crude product Substances 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 238000000605 extraction Methods 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000001962 electrophoresis Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 238000004040 coloring Methods 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 description 10
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000011632 Caseins Human genes 0.000 description 9
- 108010076119 Caseins Proteins 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 239000008351 acetate buffer Substances 0.000 description 9
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 9
- XLEYFDVVXLMULC-UHFFFAOYSA-N 2',4',6'-trihydroxyacetophenone Chemical compound CC(=O)C1=C(O)C=C(O)C=C1O XLEYFDVVXLMULC-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 150000001793 charged compounds Chemical class 0.000 description 8
- 238000006209 dephosphorylation reaction Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- -1 i.e. Proteins 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 235000021247 β-casein Nutrition 0.000 description 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- CHFRGTMFJHHWDE-UHFFFAOYSA-N 1-[bis(pyridin-2-ylmethyl)amino]-3-(pyridin-2-ylmethylamino)propan-2-ol Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CC(O)CNCC1=CC=CC=N1 CHFRGTMFJHHWDE-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 5
- 125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 235000000638 D-biotin Nutrition 0.000 description 4
- 239000011665 D-biotin Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 125000004185 ester group Chemical group 0.000 description 4
- 125000001033 ether group Chemical group 0.000 description 4
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 4
- 125000000101 thioether group Chemical group 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea group Chemical group NC(=S)N UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- HFSUHEWRFBAVHH-UHFFFAOYSA-N (4-nitropyridin-2-yl)methanol Chemical compound OCC1=CC([N+]([O-])=O)=CC=N1 HFSUHEWRFBAVHH-UHFFFAOYSA-N 0.000 description 3
- ZMMYZZKCVSFJJI-UHFFFAOYSA-N (4-nitropyridin-2-yl)methyl acetate Chemical compound CC(=O)OCC1=CC([N+]([O-])=O)=CC=N1 ZMMYZZKCVSFJJI-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- GWPGSMOIGZYFLT-UHFFFAOYSA-N 1-[(4-aminopyridin-2-yl)methyl-(pyridin-2-ylmethyl)amino]-3-[bis(pyridin-2-ylmethyl)amino]propan-2-ol Chemical compound NC1=CC=NC(CN(CC(O)CN(CC=2N=CC=CC=2)CC=2N=CC=CC=2)CC=2N=CC=CC=2)=C1 GWPGSMOIGZYFLT-UHFFFAOYSA-N 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 3
- CUBJHYMNIWGCHD-WBGPXRNDSA-N 10-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-7-carbamoyldecanoic acid Chemical compound C(=O)(O)CCCCCC(C(=O)N)CCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12 CUBJHYMNIWGCHD-WBGPXRNDSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 238000004435 EPR spectroscopy Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000030609 dephosphorylation Effects 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 150000004698 iron complex Chemical class 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000006174 pH buffer Substances 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 3
- 108091005981 phosphorylated proteins Proteins 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 239000004246 zinc acetate Substances 0.000 description 3
- 235000021249 α-casein Nutrition 0.000 description 3
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 3
- UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 2
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 2
- AYNYHZDTUORDBB-UHFFFAOYSA-N 1-[bis(pyridin-2-ylmethyl)amino]-3-[(4-nitropyridin-2-yl)methyl-(pyridin-2-ylmethyl)amino]propan-2-ol Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=C(C=1)[N+]([O-])=O)CC(O)CN(CC=1N=CC=CC=1)CC1=CC=CC=N1 AYNYHZDTUORDBB-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- OUGUTAUSQAZEJH-UHFFFAOYSA-N 2-(bromomethyl)-4-nitropyridine Chemical compound [O-][N+](=O)C1=CC=NC(CBr)=C1 OUGUTAUSQAZEJH-UHFFFAOYSA-N 0.000 description 2
- UBGCCLCUBAMUMA-UHFFFAOYSA-N 2-(bromomethyl)pyridin-3-ol Chemical compound OC1=CC=CN=C1CBr UBGCCLCUBAMUMA-UHFFFAOYSA-N 0.000 description 2
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 2
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 2
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 2
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 2
- RVFDQIIVIUKGEA-UHFFFAOYSA-N 2-[[[3-[bis(pyridin-2-ylmethyl)amino]-2-hydroxypropyl]-(pyridin-2-ylmethyl)amino]methyl]pyridin-3-ol Chemical compound C=1C=CC=NC=1CN(CC=1C(=CC=CN=1)O)CC(O)CN(CC=1N=CC=CC=1)CC1=CC=CC=N1 RVFDQIIVIUKGEA-UHFFFAOYSA-N 0.000 description 2
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 2
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 2
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100377506 Drosophila melanogaster 14-3-3zeta gene Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010044394 Hemerythrin Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- XLUMWNJFCFABKI-UHFFFAOYSA-N OC(CN(Cc1ccccn1)Cc1ncccc1)CN(Cc1ccccn1)Cc1ccccn1 Chemical compound OC(CN(Cc1ccccn1)Cc1ncccc1)CN(Cc1ccccn1)Cc1ccccn1 XLUMWNJFCFABKI-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- NJTDZCNUVXIXAT-FHZSMKFASA-N [2-[[[3-[bis(pyridin-2-ylmethyl)amino]-2-hydroxypropyl]-(pyridin-2-ylmethyl)amino]methyl]pyridin-3-yl] 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound N1=C(C=CC=C1)CN(CC(CN(CC1=NC=CC=C1OC(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12)=O)CC1=NC=CC=C1)O)CC1=NC=CC=C1 NJTDZCNUVXIXAT-FHZSMKFASA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- AOJDZKCUAATBGE-UHFFFAOYSA-N bromomethane Chemical compound Br[CH2] AOJDZKCUAATBGE-UHFFFAOYSA-N 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- YSLDOTFAFZJPOC-UHFFFAOYSA-N hydron;methyl 6-aminohexanoate;chloride Chemical compound Cl.COC(=O)CCCCCN YSLDOTFAFZJPOC-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- WIGMUEBOHBFLAH-SQWANPQRSA-N methyl 10-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-7-carbamoyldecanoate Chemical compound C(=O)(OC)CCCCCC(C(=O)N)CCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12 WIGMUEBOHBFLAH-SQWANPQRSA-N 0.000 description 2
- IRQSKJQDKUAART-UHFFFAOYSA-N methyl 6-(bromomethyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(CBr)N=C1 IRQSKJQDKUAART-UHFFFAOYSA-N 0.000 description 2
- TZJVWRXHKAXSEA-UHFFFAOYSA-N methyl 6-aminohexanoate Chemical compound COC(=O)CCCCCN TZJVWRXHKAXSEA-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 108010051423 streptavidin-agarose Proteins 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- DJWUNCQRNNEAKC-UHFFFAOYSA-L zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WFIFHOWQEJADPH-UHFFFAOYSA-N 2-chloro-4-(2-oxo-4-phenylpyrrolidin-1-yl)benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC=C1N1C(=O)CC(C=2C=CC=CC=2)C1 WFIFHOWQEJADPH-UHFFFAOYSA-N 0.000 description 1
- FTTIAVRPJGCXAC-UHFFFAOYSA-N 2-methyl-4-nitro-1-oxidopyridin-1-ium Chemical compound CC1=CC([N+]([O-])=O)=CC=[N+]1[O-] FTTIAVRPJGCXAC-UHFFFAOYSA-N 0.000 description 1
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical group CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- AUUIARVPJHGTSA-UHFFFAOYSA-N 3-(aminomethyl)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(CN)=CC2=C1 AUUIARVPJHGTSA-UHFFFAOYSA-N 0.000 description 1
- IGHBXJSNZCFXNK-UHFFFAOYSA-N 4-chloro-7-nitrobenzofurazan Chemical compound [O-][N+](=O)C1=CC=C(Cl)C2=NON=C12 IGHBXJSNZCFXNK-UHFFFAOYSA-N 0.000 description 1
- UWAUSMGZOHPBJJ-UHFFFAOYSA-N 4-nitro-1,2,3-benzoxadiazole Chemical compound [O-][N+](=O)C1=CC=CC2=C1N=NO2 UWAUSMGZOHPBJJ-UHFFFAOYSA-N 0.000 description 1
- YTCJPPMQBRNTQV-BHDMVNSNSA-N 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-[2-[[[3-[bis(pyridin-2-ylmethyl)amino]-2-hydroxypropyl]-(pyridin-2-ylmethyl)amino]methyl]pyridin-4-yl]pentanamide Chemical compound N1=C(C=CC=C1)CN(CC(CN(CC1=NC=CC(=C1)NC(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12)=O)CC1=NC=CC=C1)O)CC1=NC=CC=C1 YTCJPPMQBRNTQV-BHDMVNSNSA-N 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- GYUHKNRVDAQSOX-UHFFFAOYSA-N B=NS.COC(=O)C1=CN=C(C)C=C1.COC(=O)C1=CN=C(CBr)C=C1 Chemical compound B=NS.COC(=O)C1=CN=C(C)C=C1.COC(=O)C1=CN=C(CBr)C=C1 GYUHKNRVDAQSOX-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- UHMVYJWARHIGEX-UHFFFAOYSA-N Br.Cl.OC1=CC=CN=C1CBr.OCC1=NC=CC=C1O Chemical compound Br.Cl.OC1=CC=CN=C1CBr.OCC1=NC=CC=C1O UHMVYJWARHIGEX-UHFFFAOYSA-N 0.000 description 1
- VANAQYGZJABXKC-UHFFFAOYSA-N BrP(Br)Br.O=[N+]([O-])C1=CC(CBr)=NC=C1.O=[N+]([O-])C1=CC(CO)=NC=C1 Chemical compound BrP(Br)Br.O=[N+]([O-])C1=CC(CBr)=NC=C1.O=[N+]([O-])C1=CC(CO)=NC=C1 VANAQYGZJABXKC-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KJPRTNNQQPFDTF-UHFFFAOYSA-N C.C.C.C.COC(=O)C1=CC=C(CBr)N=C1.COC(=O)C1=CC=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1.OC(CNCC1=CC=CC=N1)CN(CC1=NC=CC=C1)CC1=NC=CC=C1 Chemical compound C.C.C.C.COC(=O)C1=CC=C(CBr)N=C1.COC(=O)C1=CC=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1.OC(CNCC1=CC=CC=N1)CN(CC1=NC=CC=C1)CC1=NC=CC=C1 KJPRTNNQQPFDTF-UHFFFAOYSA-N 0.000 description 1
- DPNAPYDUSLAFQS-UHFFFAOYSA-N C.C.C.C.O=[N+]([O-])C1=CC=NC(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)=C1.[N-]=[N+]=NC1=CC=NC(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)=C1.[N-]=[N+]=N[Na] Chemical compound C.C.C.C.O=[N+]([O-])C1=CC=NC(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)=C1.[N-]=[N+]=NC1=CC=NC(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)=C1.[N-]=[N+]=N[Na] DPNAPYDUSLAFQS-UHFFFAOYSA-N 0.000 description 1
- CGMHLZAWYJVCKS-UHFFFAOYSA-N C.C.NCCNC(=O)C1=CC=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1.O=C(NCCNC1=CC=C([N+](=O)[O-])C2=NON=C12)C1=CC=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1 Chemical compound C.C.NCCNC(=O)C1=CC=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1.O=C(NCCNC1=CC=C([N+](=O)[O-])C2=NON=C12)C1=CC=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1 CGMHLZAWYJVCKS-UHFFFAOYSA-N 0.000 description 1
- ZTIKRBUZGWEVHJ-UHFFFAOYSA-N C.C.O=[N+]([O-])C1=CC(CBr)=NC=C1.O=[N+]([O-])C1=CC=NC(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)=C1.OC(CNCC1=CC=CC=N1)CN(CC1=NC=CC=C1)CC1=NC=CC=C1 Chemical compound C.C.O=[N+]([O-])C1=CC(CBr)=NC=C1.O=[N+]([O-])C1=CC=NC(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)=C1.OC(CNCC1=CC=CC=N1)CN(CC1=NC=CC=C1)CC1=NC=CC=C1 ZTIKRBUZGWEVHJ-UHFFFAOYSA-N 0.000 description 1
- DNBAFELCENOUKQ-UHFFFAOYSA-N CC(=O)OC(C)=O.CC(=O)OCC1=NC=CC([N+](=O)[O-])=C1.CC1=[N+]([O-])C=CC([N+](=O)[O-])=C1 Chemical compound CC(=O)OC(C)=O.CC(=O)OCC1=NC=CC([N+](=O)[O-])=C1.CC1=[N+]([O-])C=CC([N+](=O)[O-])=C1 DNBAFELCENOUKQ-UHFFFAOYSA-N 0.000 description 1
- DRLQJGCDEZPZGD-UHFFFAOYSA-N CC(=O)OCC1=NC=CC([N+](=O)[O-])=C1.Cl.O=[N+]([O-])C1=CC(CO)=NC=C1 Chemical compound CC(=O)OCC1=NC=CC([N+](=O)[O-])=C1.Cl.O=[N+]([O-])C1=CC(CO)=NC=C1 DRLQJGCDEZPZGD-UHFFFAOYSA-N 0.000 description 1
- YRPBAOFSFMHOQX-UHFFFAOYSA-N CC(Nc(cc1C(O)=O)ccc1C(c(c(O1)c2)ccc2O)=C(C=C2)C1=CC2=O)=S Chemical compound CC(Nc(cc1C(O)=O)ccc1C(c(c(O1)c2)ccc2O)=C(C=C2)C1=CC2=O)=S YRPBAOFSFMHOQX-UHFFFAOYSA-N 0.000 description 1
- VRFRDLLZIXGUQQ-UHFFFAOYSA-N CN(C)C1=CC=CC2=C(S(=O)(=O)NCCNC(=O)C3=CC=C(CN(CC4=CC=CC=N4)CC(O)CN(CC4=NC=CC=C4)CC4=NC=CC=C4)N=C3)C=CC=C12.NCCNC(=O)C1=CC=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1 Chemical compound CN(C)C1=CC=CC2=C(S(=O)(=O)NCCNC(=O)C3=CC=C(CN(CC4=CC=CC=N4)CC(O)CN(CC4=NC=CC=C4)CC4=NC=CC=C4)N=C3)C=CC=C12.NCCNC(=O)C1=CC=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1 VRFRDLLZIXGUQQ-UHFFFAOYSA-N 0.000 description 1
- SBINKOWMAZCLMP-UHFFFAOYSA-N CO.COC(=O)CCCCCN.COC(=O)CCCCCN.Cl.Cl.NCCCCCC(=O)O.O=S(=O)(O)O Chemical compound CO.COC(=O)CCCCCN.COC(=O)CCCCCN.Cl.Cl.NCCCCCC(=O)O.O=S(=O)(O)O SBINKOWMAZCLMP-UHFFFAOYSA-N 0.000 description 1
- JQOCSLUFGOYGBI-UHFFFAOYSA-N COC(=O)C1=CC=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1.NCCNC(=O)C1=CC=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1 Chemical compound COC(=O)C1=CC=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1.NCCNC(=O)C1=CC=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1 JQOCSLUFGOYGBI-UHFFFAOYSA-N 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- WGWJQRNJRWJBFC-SOUDXTIDSA-N NC1=CC=NC(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)=C1.[H][C@]12NC(=O)N[C@@]1([H])CSC2CCCCC(=O)NC1=CC=NC(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)=C1 Chemical compound NC1=CC=NC(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)=C1.[H][C@]12NC(=O)N[C@@]1([H])CSC2CCCCC(=O)NC1=CC=NC(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)=C1 WGWJQRNJRWJBFC-SOUDXTIDSA-N 0.000 description 1
- KKNWPNJFANDETR-GCMUWJJZSA-N NC1=CC=NC(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)=C1.[H][C@]12NC(=O)N[C@@]1([H])CSC2CCCCC(=O)NCCCCCC(=O)NC1=CC=NC(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)=C1 Chemical compound NC1=CC=NC(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)=C1.[H][C@]12NC(=O)N[C@@]1([H])CSC2CCCCC(=O)NCCCCCC(=O)NC1=CC=NC(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)=C1 KKNWPNJFANDETR-GCMUWJJZSA-N 0.000 description 1
- DRCHERDQORFIRX-UHFFFAOYSA-N NCC(O)CN.O=CC1=CC=CC=N1.OC(CNCC1=CC=CC=N1)CN(CC1=NC=CC=C1)CC1=NC=CC=C1 Chemical compound NCC(O)CN.O=CC1=CC=CC=N1.OC(CNCC1=CC=CC=N1)CN(CC1=NC=CC=C1)CC1=NC=CC=C1 DRCHERDQORFIRX-UHFFFAOYSA-N 0.000 description 1
- QIPRXTNEDKJZST-UHFFFAOYSA-N NCCNC(=O)C1=CC=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1.O=C1C=CC2=C(C3=CC=C(NC(=S)NCCNC(=O)C4=CC=C(CN(CC5=CC=CC=N5)CC(O)CN(CC5=NC=CC=C5)CC5=NC=CC=C5)N=C4)C=C3C(=O)O)C3=CC=C(O)C=C3OC2=C1 Chemical compound NCCNC(=O)C1=CC=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=C1.O=C1C=CC2=C(C3=CC=C(NC(=S)NCCNC(=O)C4=CC=C(CN(CC5=CC=CC=N5)CC(O)CN(CC5=NC=CC=C5)CC5=NC=CC=C5)N=C4)C=C3C(=O)O)C3=CC=C(O)C=C3OC2=C1 QIPRXTNEDKJZST-UHFFFAOYSA-N 0.000 description 1
- POIDYVQWGQCVEB-GCMUWJJZSA-N NCCNC(=O)C1=CN=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=CC=CC=N2)CC2=NC=CC=C2)C=C1.[H][C@]12NC(=O)N[C@@]1([H])CSC2CCCCC(=O)NCCCC(=O)NCCNC(=O)C1=CN=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=CC=CC=N2)CC2=NC=CC=C2)C=C1 Chemical compound NCCNC(=O)C1=CN=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=CC=CC=N2)CC2=NC=CC=C2)C=C1.[H][C@]12NC(=O)N[C@@]1([H])CSC2CCCCC(=O)NCCCC(=O)NCCNC(=O)C1=CN=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=CC=CC=N2)CC2=NC=CC=C2)C=C1 POIDYVQWGQCVEB-GCMUWJJZSA-N 0.000 description 1
- 241000692885 Nymphalis antiopa Species 0.000 description 1
- ZOOWDBBMSJIOPW-BHDMVNSNSA-N OC(CN(Cc1ccccn1)Cc1ccccn1)CN(Cc1ncccc1)Cc(cc1)ncc1C(NCCNC(CC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)=O)=O Chemical compound OC(CN(Cc1ccccn1)Cc1ccccn1)CN(Cc1ncccc1)Cc(cc1)ncc1C(NCCNC(CC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)=O)=O ZOOWDBBMSJIOPW-BHDMVNSNSA-N 0.000 description 1
- OGOZOPKYJIIQBH-UHFFFAOYSA-N OC(CNCC1=CC=CC=N1)CN(CC1=NC=CC=C1)CC1=NC=CC=C1.OC1=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=CC=C1.OC1=CC=CN=C1CBr Chemical compound OC(CNCC1=CC=CC=N1)CN(CC1=NC=CC=C1)CC1=NC=CC=C1.OC1=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=CC=C1.OC1=CC=CN=C1CBr OGOZOPKYJIIQBH-UHFFFAOYSA-N 0.000 description 1
- HEOJJHMWQVCJLF-BFQDCSMCSA-N OC1=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=CC=C1.[H][C@]12NC(=O)N[C@@]1([H])CSC2CCCCC(=O)OC1=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=CC=C1 Chemical compound OC1=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=CC=C1.[H][C@]12NC(=O)N[C@@]1([H])CSC2CCCCC(=O)OC1=C(CN(CC2=CC=CC=N2)CC(O)CN(CC2=NC=CC=C2)CC2=NC=CC=C2)N=CC=C1 HEOJJHMWQVCJLF-BFQDCSMCSA-N 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- DLGYNVMUCSTYDQ-UHFFFAOYSA-N azane;pyridine Chemical compound N.C1=CC=NC=C1 DLGYNVMUCSTYDQ-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- SKVRYQUMKJQZFN-UHFFFAOYSA-N hydron;2-(hydroxymethyl)pyridin-3-ol;chloride Chemical compound Cl.OCC1=NC=CC=C1O SKVRYQUMKJQZFN-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- IJJDPBVDJXYHMJ-UHFFFAOYSA-N methyl 6-[[[3-[bis(pyridin-2-ylmethyl)amino]-2-hydroxypropyl]-(pyridin-2-ylmethyl)amino]methyl]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1CN(CC=1N=CC=CC=1)CC(O)CN(CC=1N=CC=CC=1)CC1=CC=CC=N1 IJJDPBVDJXYHMJ-UHFFFAOYSA-N 0.000 description 1
- 125000006362 methylene amino carbonyl group Chemical group [H]N(C([*:2])=O)C([H])([H])[*:1] 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- AJUXDFHPVZQOGF-UHFFFAOYSA-N n,n-dimethyl-1-naphthylamine Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1 AJUXDFHPVZQOGF-UHFFFAOYSA-N 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003799 water insoluble solvent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6596—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having atoms other than oxygen, sulfur, selenium, tellurium, nitrogen or phosphorus as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/805—Optical property
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Definitions
- the present, invention relates to a method for labeling phosphorylated peptides, a method for selectively adsorbing phosphorylated peptides, complex compounds usable in the methods, a process for producing the complex compounds, and compounds usable as a raw material in the production process.
- One of the examples of the metabolic systems which are controlled by the aforementioned phosphorylation-dephosphorylation is a system of suppressing synthesis of glycogen and decomposing the same. This metabolic system is primarily cascade-controlled by the phosphorylation-dephosphorylation.
- one of the causes of cell carcinogenesis is abnormality in the phosphorylation-dephosphorylation.
- progress and stop of cell cycle are controlled by phosphorylation or dephosphorylation of various enzymes, i.e., proteins.
- Cycline and cycline-dependent kinase (CDK) are relevant factors in the phosphorylation or dephosphorylation. If the mechanism relating to cycline and CDK is impaired, phosphorylation or dephosphorylation may be uncontrollable, thereby triggering abnormal proliferation of cells.
- protein kinase C is related with degranulation of histamine causative of allergic disorders such as atopic dermatitis and pollen allergy, and that phosphorylated tau-protein is causative of neurofibrillary tangle in the brains of Alzheimer's patients.
- the document Morio YASHIRO, et al. ⁇ Preparation and Study of Dinuclear Zinc(II) Complex for the Efficient Hydrolysis of the Phosphodiester Linkage in a Diribonucleotide ⁇ , Journal of the Chemical Society, Chemical communications. pp. 1793-1794 (1995), recites a zinc complex.
- the zinc complex has a function that two zinc ions in the complex dissociate a phosphoric acid group, namely, phosphoric diester, from dinucleotide.
- the function of the zinc complex disclosed in the document is merely a catalyst.
- the document dose not disclose the ability of the zinc complex to bond coordinately to a phosphoric acid group.
- the experiments conducted by the inventors reveal that a dissociation constant of the zinc complex to a phosphoric acid group sandwiched by two nucleosides, namely, a phosphoric diester is extremely high.
- the zinc complex has a low coordinatability to a phosphoric diester moiety.
- R 1 and R 2 each is a reactive group for forming the linker moiety X, and Y is a labeling group.
- R 1 is a reactive group except an aminomethyl group, a hydroxymethyl group, an amino group, and a carboxyl group.
- the phosphorylated peptide namely, a protein can be easily detected.
- the present invention is useful in diagnosing diseases or the like with use of samples derived from living organisms or the like.
- inventive compound (I) shows a unique coordination bond to the two hydroxy groups in a phosphoric monoester moiety or phosphoric ion
- inventive compound (I) is useful as a compound usable in the inventive method.
- inventive compound (I) is useful for purifying or concentrating phosphorylated peptide and obtaining the chemical information of phosphorylated peptide.
- FIG. 1 is an illustration showing a result of examination by an MALDI-TOF mass spectrometer regarding a zinc complex according to the present invention.
- FIG. 2 is an illustration showing electrophoresis gels, which is dyed by the inventive zinc complex (A) and further conventional dye (B). This illustration makes it clear that the inventive method can identify only phosphorylated peptide, while conventional method dyes all of the peptide.
- FIG. 3 is an illustration showing a result of examination by the MALDI-TOF mass spectrometer regarding a zinc complex according to the present invention, as well as an enlarged illustration showing a certain region of the examination result.
- FIG. 4 is an illustration showing a result of examination by the MALDI-TOF mass spectrometer regarding a zinc complex according to the present invention, as well as an enlarged illustration showing a certain region of the examination result.
- FIG. 5 is an illustration showing a result of examination by the MALDI-TOF mass spectrometer regarding the raw material compound used in producing the inventive compound having biotin as a labeling group, as well as an enlarged illustration showing a certain region of the examination result.
- FIG. 6 is an illustration showing a result of examination by the MALDI-TOF mass spectrometer regarding the raw material compound used in producing the inventive compound having biotin as a labeling group, as well as an enlarged illustration showing a certain region of the examination result.
- FIG. 7 is an illustration showing a result of examination by the MALDI-TOF mass spectrometer regarding a zinc complex according to the present invention, as well as an enlarged illustration showing a certain region of the examination result.
- FIG. 8 is an illustration showing a result of examination by the MALDI-TOF mass spectrometer regarding a zinc complex according to the present invention.
- FIG. 9 is an illustration showing electrophoresis gels, which is dyed by the inventive zinc complex (A) and further conventional dye (B). This illustration makes it clear that the inventive method can identify only phosphorylated peptide, while conventional method dyes all of the peptide.
- a primary feature of the inventive method resides in that a phosphorylated peptide can be easily identified by forming a composite compound in which a complex compound having a labeling group as represented by the formula (I) is specifically bonded to the phosphorylated peptide.
- prepared is a sample containing substantially all the possible kinds of peptides constituting a tissue cell to be examined.
- the preparation can be conducted according to a conventional method practiced in the biochemistry.
- the separation method is not specifically limited, and a conventional separation method such as electrophoresis can be applied.
- the gel after the electrophoresis is immersed in a solution containing the complex compound represented by the formula (I) to label the phosphorylated peptide, and then, the phosphorylated peptide is detected by a detecting method depending on the kind of the labeling group.
- a solvent usable in the solution containing the complex compound represented by the formula (I) is not specifically limited, as far as the solvent does not hinder detection of the phosphorylated peptide.
- Water including a buffer and a solution containing a salt other than a buffer; alcohols such as methanol and ethanol; and a mixed solvent containing these components are examples of the solvent.
- an aqueous solvent is used primarily for the purpose of preventing denaturation of the peptide.
- Zn is selected as a coordinate metal because Zn is highly coordinated to a phosphoric acid group in a phosphorylated protein. namely, a phosphoric monoester moiety.
- the linker moiety in the present specification and the claims means a group capable of linking a main skeleton and a labeling group.
- the linker moiety facilitates production of the compound (I), and inhibits the labeling group from hindering coordination of the compound (I) to the phosphoric acid group bonded to the peptide.
- the linker moiety may be a coordination bond which directly links the main skeleton and the labeling group if it is easy to obtain a raw material compound in which a labeling group is directly linked to a main skeleton in synthesizing the compound (I), or if the labeling group is of such a small size that hindrance of coordination of the compound (I) to the phosphoric acid group is securely prevented.
- linker moiety in the present specification and the claims is not specifically limited, as far as the linker moiety has the above functions.
- Examples of the linker moiety are: a C1-C6 alkylene group, an amino group (—NH—), an ether group (—O—), a thioether group (—S—), a carbonyl group (—C( ⁇ O)—), a thionyl group (—C( ⁇ S)—), an ester group, an amide group, a urea group (—NHC( ⁇ O)NH—), a thiourea group (—NHC( ⁇ S)NH—); a C1-C6 alkylene group having, at one end thereof, a group selected from the group consisting of an amino group, an ether group, a thioether group, a carbonyl group, a thionyl group, an ester group, an amide group, a urea group, and a thiourea group; a
- the C1-C6 alkylene group means a bivalent aliphathic hydrocarbon group having 1 to 6 carbon atoms of a straight chain or a branched chain, such as methylene, ethylene, propylene, tetramethylene, hexamethylene, methylethylene, methylpropylene, and dimethylpropylene, and preferably is a C1-C4 alkylene group, and more preferably is a C1-C2 alkylene group.
- the labeling group in the present specification and the claims is not specifically limited, as far as it is generally used in the biochemistry. However, a compound containing a radioisotope is not preferable in the aspect of handling. Examples of the labeling group are a fluorescent group, a group containing a nitro oxide radical and biotin.
- the fluorescent group is a substituent capable of stably generating fluorescence of a relatively long wavelength, and a group generally used in the biochemistry can be unlimitedly used as the fluorescent group, irrespective of the property that the compound is soluble in water or oil.
- Examples of the fluorescent group are aminomethylcoumarin and its derivatives, fluoroscein and its derivatives, tetramethylrhodamine and its derivatives, anthraniloyl and its derivatives, nitrobenzoxadiazole and its derivatives, and dimethylaminonaphthalene and its derivatives.
- the group containing a nitro oxide radical is a group having a stable radical, and is capable of detecting a phosphorylated peptide by electron spin resonance (ESR).
- ESR electron spin resonance
- a biological molecule does not show electron spin resonance because it does not have an unpaired electron.
- a peptide bonded by the compound (I) having a nitro oxide radical being coordinated thereto shows electron spin resonance, the phosphorylated peptide is identifiable.
- Biotin has specific and high affinity to avidin derived from albumen and streptoavidin derived from actinomycetes.
- the inventive complex compound can be specifically bonded to an enzyme by way of biotin and avidin or streptoavidin, by bonding avidin or streptoavidin to the inventive compound (I) having biotin as a labeling group and further bonding a biotinated enzyme.
- the phosphorylated peptide can be identified by using the enzyme such as alkaliphosphotase, peroxidase and luciferase, and by using a coloring reagent depending on the kind of the enzyme.
- the complex compound is bonded by alkaliphosphotase as the enzyme via streptoavidin, further nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate as the coloring reagents are added, and the mixture is reacted for several hours, the phosphorylated peptide turns into purple, thereby making it possible to identify the phosphorylated peptide.
- streptoavdin labeled with a fluorescent pigment such as rhodamine is commercially available. Use of the streptoavidin labeled with the fluorescent pigment makes it possible to identify a phosphorylated peptide by a known fluorescent image analyzing method.
- the method for selectively adsorbing phosphorylated peptides, biotin or the like capable of specifically being bonded to a specific compound is used as a labeling group.
- an agarose gel with streptoavidin being bonded thereto is commercially available.
- An agarose gel with the inventive complex compound being bonded thereto can be obtained by applying the inventive complex compound having biotin as a labeling group to an agarose gel for reaction.
- the phosphorylated peptide in a mixed sample can be selectively adsorbed to the inventive complex compound by applying the mixed sample to the agarose gel.
- a phosphoric acid buffer or the like capable of desorbing the phosphorylated peptide from the inventive complex compound makes it possible to obtain the phosphorylated peptide exclusively In this way, using the agarose gel is advantageous in purifying or concentrating a phosphorylated peptide without electrophoresis.
- magnetic beads with streptoavidin being bonded thereto are commercially available. Use of the magnetic beads also makes it possible to purify or concentrate a phosphorylated peptide. Further, plates with streptoavidin being bonded thereto are commercially available for measuring surface plasmon resonance (SPR).
- a plate with the inventive complex compound being bonded thereto for measuring surface plasmon resonance can be obtained by applying the inventive complex compound having biotin as a labeling group onto the plate. Presence or absence of the phosphorylated peptide in a sample can be detected by measuring the surface plasmon resonance (SPR) of the plate.
- SPR surface plasmon resonance
- the location of the (—X—Y) group in the inventive compound is not specifically limited.
- the (—X—Y) group may be located at the site as shown in the compound (I′).
- the compound (I) and the compound (I′) are substantially equivalent to each other. Although it is not clear as to which compound is synthesized, the compound (I) or the compound (I′), what is actually synthesized is conceivably a synthesized mixture of the compound (I) and the compound (I′). It is needless to say that the compound (I′) is embraced in the scope of the present invention.
- a complex compound represented by the formula (I) can be easily produced by a process comprising Scheme 1.
- the labeling group Y is introduced to the main skeleton via the linker moiety X by reacting the reactive groups R 1 and R 2 .
- the kind of R 1 , R 2 , the solvent, a reaction temperature, a reagent other than the above, a purification method, and other factors are primarily determined by the kind of X.
- a labeling group via an amino group a secondary or tertiary amino group
- a combination of R 1 and R 2 a combination of a group having an amino group (a primary or a secondary amino group) at a distal end thereof and a elimination group such as a halogen atom.
- Condensing R 1 and R 2 under the presence of basic groups in the solvent is an example of general reaction condition. In case that R 1 is an active group, it is very easy to introduce a labeling group.
- the compound (I) can be synthesized by adding a metallic salt to a solution containing the compound (IV).
- Zinc (II) nitrate or zinc (II) acetate may be added as the metallic salt.
- zinc (II) acetate a compound represented by the following formula (V) in which acetic acid is temporarily coordinated is produced.
- the compound (V) is chemically more stable than the compound (I), and accordingly useful in storage.
- the compound (V) is equivalent to the compound (I), and is usable in the similar manner as the compound (I). Specifically, by adding the compound (V) to the mixture containing the peptide, the phosphorylated peptide can be detected because the phosphoric monoester moiety is interchangeably coordinated to the compound (I) in place of the acetic acid.
- the compound (II), namely, a raw material compound of the compound (I) can be synthesized by the following Scheme 2.
- R 1 is the same as defined above, and “Hal” is a halogen atom, and preferably is a bromine.
- the compound (VI), i.e., 1,3-diamino-2-propanol, as a raw material compound may be commercially available. Further, since both the compound (VII) and the compound (IX) have a relatively simple structure, the compound (VII) and (IX) may be commercially available, or can be synthesized by a well-known method for a person skilled in the art.
- reductive amination is carried out as a condensation reaction.
- a solvent used in the reductive amination is not specifically limited, as far as the solvent is capable of substantially dissolving the compound (VI) and the compound (VII), and does not inhibit the amination.
- alcohols such as methanol, ethanol and isopropanol
- ethers such as diethyl ether, tetrahydrofuran and dioxane
- water or a mixed solvent containing two or more of these components can be used as the solvent.
- the reductive amination can be carried out with use of a conventional reducing reagent after condensing the compound (VI) and the compound (VII) under the presence of concentrated hydrochloric acid, as a catalyst.
- reaction temperature and the reaction time can be optionally selected depending on the kind of the raw material compound or other factors.
- the reaction may be carried out at a reaction temperature from 20 to 80° C. for a reaction time from 12 to 100 hours.
- the solvent and the like are distilled off under depressurization before adding water. After water is added, the resultant mixture is extracted with a water-insoluble solvent, and the organic layer is dried over anhydrous magnesium sulfate or the like. Thereafter, the solvent is distilled off under depressurization. Subsequently, the residue is purified by a well known process such as silica gel column chromatography, thereby to yield the compound (VIII).
- the process for yielding the compound (VIII) is not limited to the process as shown by Scheme 2.
- the compound (VIII) may be synthesized using the compound (VI) and a halogen compound, for example.
- the compound (II) can be synthesized by reacting the compound (VIII) with the compound (IX). This reaction can be carried out by a know process of synthesizing tertiary amines. For instances the compound (VIII) and the compound (IX) are condensed under the presence of base in a solvent. In the condensing step, a protective group may be introduced and cleaved depending on the kind of R 1 according to needs.
- the compound (II) may be synthesized by implementing the condensing step with use of a compound having an inactive substituent group in place of using R 1 in the compound (IX), and by substituting R 1 for the inactive substituent group by functional group conversion. For instance, the condensing step is implemented by using a compound having a nitro group as the inactive substituent group and by substituting an amino group as the reactive group for the nitro group.
- the complex compound (X) used in the inventive method is electrically enriched with pyridine nitrogen by the electron donating substituent group that has been introduced to an appropriate position for substitution. Accordingly, the complex compound (X) used in the inventive method is highly coordinated to zinc, thereby, making it possible to produce the complex compound (X) easily, while providing stability.
- a manner of using the complex compound (X), a process for producing the complex compound (X), and a raw materiel compound for the complex compound (X) are substantially the same as those regarding the complex compound (I).
- biotin as the labeling group, in producing the complex compound.
- Use of biotin is preferred because biotin is easy to be handled, and has high usability in the point that it exhibits various colorings reactions.
- Use of biotin is effective in easily identifying the phosphorylated peptide.
- N,N,N′-tri(2-pyridylmethyl)-1,3-diaminopropane-2-ol (18.2 g, 50 mmol) obtained in Production Example 1-2 in dried dimethylformamide (150 mL), was added potassium carbonate (13.8 g, 100 mmol), followed by addition of a solution of the methyl 6-bromomethylnicotinate (11.5 g, 50 mmol) obtained in Production Example 1-1 in dried dimethylformamide (75 mL) dropwise. After the dropwise addition was completed, the mixture was reacted at 50° C. for 1 hour.
- the solution was cooled. Then, the cooled solution was poured into 750 mL of water, and the pH of the solution was adjusted to 8 by adding 1N hydrochloric acid. After extraction with ethyl acetate, the extracts were collected, washed with water and brine, and concentrated. The residue obtained by the concentration was purified by silica gel column chromatography, thereby to yield 21.5 g of the target compound.
- N,N,N′-tri(2-pyridylmethyl)-N′-(5-methoxycarbonyl-2-pyridylmethyl)-1,3-diaminopropane-2-ol (9.7 g, 18.9 mmol) obtained in Production Example 1-3 in methanol (100 mL), was added ethylenediamine (22.7 g, 378 mmol) dropwise. After the dropwise addition, the mixture was reacted at room temperature for 3 days.
- the inventive zinc complex in the solution exhibits the following structure, and was identified by MALDI-TOF mass spectrometer (Matrix: 2′,4′,6′-trihydroxyacetophenone, Mode: reflector, Accelerating Voltage: 20000V, Grid Voltage: 57.500%, Laser: 2500, Scans Averaged: 128, Pressure: 5.05e-07).
- FIG. 1 The result of measurement by the MALDI-TOF mass spectrometer is shown in FIG. 1. As shown in FIG. 1, a molecular ion peak at 926.2 (exact mass: 926.11) was observed. It is considered that a molecular ion peak at 910.2 appeared because the oxygen in the oxadiazole group was eliminated.
- the inventive zinc complex in the solution exhibits the following chemical structure, and was identified by the MALDI-TOF mass spectrometer (Matrix: 2′,4′,6′-trihydroxyacetophenone).
- FIG. 3 A result of measurement by the MALDI-TOF mass spectrometer is shown in FIG. 3. As shown in FIG. 3, a molecular ion peak at 989.6 (exact mass: 989.19) is observed.
- pH buffer for electrophoresis pH 8.3
- the gel was immersed in the zinc-complex-containing solution (50 ⁇ M) obtained in Production Example 1-6 for about 30 minutes. Then, the gel was taken out from the solution, and photographed under irradiation by a UV lamp. Further, the gel was dyed with Coomassie brilliant blue according to a conventional dying process, and the dyed gel was photographed.
- the gel dyed with the zinc-complex-containing solution is referred to as “gel A”, and the gel dyed with Coomassie brilliant blue is referred to as “gel B”, both of which are shown in FIG. 2.
- the solution was analyzed by the MALDI-TOF mass spectrometer (matrix: 2′,4′,6′-trihydroxyacetophenone), and the zinc complex was identified.
- a result of measurement by the MALDI-TOF mass spectrometer is shown in FIG. 4. As shown in FIG. 4, a molecular ion peak at 1102.3 (exact mass: 1102.27) was observed.
- inventive complex compound can adsorb selectively a phosphorylated peptide and use of the inventive complex compound is advantageous in selectively isolating the phosphorylated peptide in a mixed sample of the phosphorylated peptide and the non-phosphorylated peptide.
- the reaction mixture was poured into 250 mL of ice-cold water, and the pH of the aqueous layer was adjusted to 8 by adding sodium hydrogencarbonate. After the ether layer and the aqueous layer were separated, the aqueous layer was extracted with 100 mL of ethyl acetate twice. The organic layers were collected, and dried over anhydrous sodium sulfate. After the solvent was distilled off, the crude product was purified by silica gal column chromatography, thereby to yield 0.80 g of the target compound.
- the reaction mixture was poured into 200 mL of water, and the pH of the mixture was adjusted to 8 by adding 1N hydrochloric acid. After extraction with 400 mL of ethyl acetate for three times, the organic layer was washed with 250 mL of brine. After being dried over anhydrous magnesium sulfate, the organic layer was concentrated. After the solvent was distilled off, the crude product was purified by silica gel column chromatography, thereby to yield 3.30 g of the target compound.
- N,N,N′-tri(2-pyridylmethyl) -N′-(4-nitro-2-pyridylmethyl)-1,3-diaminopropane-2-ol (1.01 g, 2.00 mmol) obtained in Production Example 4-4 in dried tetrahydrofuran (17 mL), was added sodium azide (156 mg, 2.40 mmol) in water (3.3 mL) dropwise at room temperature. The reaction mixture was heated to 50° C., and reacted at the same temperature, i.e., 50° C. for 17 hours.
- N,N,N′-tri(2-pyridylmethyl)-N′-(4-azide-2-pyridylmethyl)-1,3-diaminopropane-2-ol 980 mg, 1.98 mmol obtained in Production Example 4-5 in ethanol (20 mL), was added 100 mg of platinum oxide. The mixture was reacted under hydrogen pressure of 30 kPa for 2 hours. After the catalyst (platinum oxide) was removed by filtration, the filtrate was concentrated, and the resulting crude product was purified by silica gel column chromatography, thereby to yield 690 mg of the target compound.
- 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 49.0 mg, 0.26 mmol was added at room temperature. The reaction mixture was heated, and reacted under reflux for 5 hours. To the reaction mixture, were added D-biotin (6.0 mg, 0.02 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (10.0 mg, 0.05 mmol), and 2 mL of dichloromethane, followed by reaction under reflux for 6 hours.
- This compound was examined by the MALDI-TOF mass spectrometer using ⁇ -cyano-4-hydroxycinnamic acid (CHCA) as a matrix. A result of measurement is shown in FIG. 5. As is obvious from FIG. 5, a molecular ion peak 696.2 of proton adduct ion (M + +1) was observed.
- CHCA ⁇ -cyano-4-hydroxycinnamic acid
- reaction mixture was poured into 300 mL of water, and extracted with 150 mL of chloroform for 5 times. After the extracts were dried over anhydrous magnesium sulfate and the solvent was distilled off. The resulting crude product was purified by silica gel column chromatography, thereby to yield 1.04 g of the target compound.
- reaction mixture was concentrated, followed by addition of 60 mL of water. Then, 1N hydrochloric acid was added, and the pH of the mixture was adjusted to 2.0. The precipitated crystals were isolated by filtration and washed with water. The obtained crystals were dried in vacuo, thereby to yield 724 mg of the target compound.
- reaction mixture was poured into 50 mL of water, and the pH of the mixture was adjusted to 8 by adding saturated aqueous sodium hydrogencarbonate solution. After extraction with 50 mL of dichloromethane for four times, the dichloromethane layers were concentrated. The crude product after the concentration was purified by silica gel column chromatography, thereby to yield 1.36 g of the target compound.
- the reaction mixture was poured into 100 mL of water, and the pH of the mixture was adjusted to 8 by adding 1N hydrochloric acid. After extraction with 100 mL of ethyl acetate for three times, the organic layers were washed with 100 mL of water and 100 mL of brine, and dried over anhydrous sodium sulfate. The obtained crude product was purified and collected by HPLC, thereby to yield 660 mg of the target compound.
- N,N,N′-tri(2-pyridylmethyl)-N′-(3-hydroxy-2-pyridylmethyl)-1,3-diaminopropane-2-ol 100 mg, 0.21 mmol obtained in Production Example 6-2 in dried dimethylformamide (5 mL), was added sodium hydride (dispersion in mineral oil) (9.0 mg, 0.23 mmol) at 3° C. After the temperature was returned to room temperature, the mixture was reacted at room temperature for 30 minutes, followed by addition of a solution of N-succinimidyl D-biotinate (79.8 mg, 0.23 mmol) in dried dimethylsulfoxide (1 mL) dropwise.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
- 1. Field of the Invention
- The present, invention relates to a method for labeling phosphorylated peptides, a method for selectively adsorbing phosphorylated peptides, complex compounds usable in the methods, a process for producing the complex compounds, and compounds usable as a raw material in the production process.
- 2. Description of the Related Art
- There are known in vivo enzymes having serine, threonine or tyrosine residue at a specific site corresponding to an active center or allosteric site. The enzymatic activity of these enzymes is controlled by phosphorylating or dephosphorylating hydroxyl group in these residues by an enzyme called kinase and the like. Also, there are known enzymes whose enzymatic activity is controlled by phosphorylating or dephosphorylating an amino group or an imino group in lysin, arginine or histidine, or a carboxyl group in aspartic acids or glutamic acids.
- One of the examples of the metabolic systems which are controlled by the aforementioned phosphorylation-dephosphorylation is a system of suppressing synthesis of glycogen and decomposing the same. This metabolic system is primarily cascade-controlled by the phosphorylation-dephosphorylation.
- A recent study elucidated that the phosphorylation-dephosphorylation plays a significant role in disease-related metabolic systems.
- For instance, it is said that one of the causes of cell carcinogenesis is abnormality in the phosphorylation-dephosphorylation. Specifically, progress and stop of cell cycle are controlled by phosphorylation or dephosphorylation of various enzymes, i.e., proteins. Cycline and cycline-dependent kinase (CDK) are relevant factors in the phosphorylation or dephosphorylation. If the mechanism relating to cycline and CDK is impaired, phosphorylation or dephosphorylation may be uncontrollable, thereby triggering abnormal proliferation of cells.
- In addition to the above, facts are known that protein kinase C is related with degranulation of histamine causative of allergic disorders such as atopic dermatitis and pollen allergy, and that phosphorylated tau-protein is causative of neurofibrillary tangle in the brains of Alzheimer's patients.
- In view of the above , comprehending the condition of phosphorylation-dephosphorylation of proteins provides useful measures not only in investigating expression of genes in living tissue cells and evaluating the enzymatic activity of the cells, but also in diagnosing diseases or medical treatment.
- The conventional methods for identifying phosphorylated proteins or dephosphorylated proteins have various drawbacks.
- For instance, while an enzyme immunoassay is advantageous in analyzing a target protein sample of a very small amount, it is difficult to obtain antibodies of the target protein of a sufficient amount. Further, in case that the level of the target protein is several kDa or lower, it is impossible to prepare an antibody that is securely bonded to a site in the protein where phosphorylation occurs.
- There is proposed a method for detecting a protein specifically bonded by a phosphoric acid with use of a phosphoric acid labeled with a radioactive isotope32P. However, special attention should be paid in handling radioactive isotopes, and appropriate administration and disposal of waste liquid of the radioactive isotopes are required.
- There is proposed an idea of applying two-dimensional electrophoresis in view of the fact that electric charges are differentiated between phosphorylated proteins and dephosphorylated proteins. However, it is extremely difficult to identify the band or spot of a phosphorylated or dephosphorylated protein in analyzing a sample derived from a living organism, because the sample contains a variety of proteins. Furthermore, use of a radioactive isotope to identify the band or spot involves the aforementioned problems.
- The document, Morio YASHIRO, et al. ┌Preparation and Study of Dinuclear Zinc(II) Complex for the Efficient Hydrolysis of the Phosphodiester Linkage in a Diribonucleotide┘, Journal of the Chemical Society, Chemical communications. pp. 1793-1794 (1995), recites a zinc complex. The zinc complex has a function that two zinc ions in the complex dissociate a phosphoric acid group, namely, phosphoric diester, from dinucleotide. However, the function of the zinc complex disclosed in the document is merely a catalyst. The document dose not disclose the ability of the zinc complex to bond coordinately to a phosphoric acid group. The experiments conducted by the inventors reveal that a dissociation constant of the zinc complex to a phosphoric acid group sandwiched by two nucleosides, namely, a phosphoric diester is extremely high. In other words, the zinc complex has a low coordinatability to a phosphoric diester moiety.
- Further, the document, Hidekazu ARII, et al., ┌A novel diiron complex as a functional model for hemerythrin┘. Journal of Inorganic Biochemistry, 82, pp. 153-162 (2000), recites an iron complex having a structure analogous to the structure of the zinc complex. The iron complex, however, is a product synthesized as a model of hemerythrin, namely, a carrier protein carrying oxygen molecules. As is the case with the above mentioned document, this document neither discloses nor remotely suggests coordinate bond of the iron complex to a phosphoric monoester moiety.
- In view of the above, it is an object of the present invention to overcome the problems residing in the prior art. It is another object of the present invention to provide a method for labeling phosphorylated peptides, namely, proteins, for easy detection, and a method for selectively adsorbing the phosphorylated peptides for purification or the like.
- It is still another object of the present invention to provide compounds that are capable of being highly coordinated to the phosphorylated peptides and usable in the labeling method and the selective adsorbing method, a process for producing the compounds, and raw material compounds usable in the production process.
-
- wherein X is a linker moiety, and Y is a labeling group.
- According to another aspect of the present invention, provided is a method for selectively adsorbing a phosphorylated peptide by using the above complex compound.
- According to yet another aspect of the present invention, provided is the above complex compound.
-
- wherein R1 and R2 each is a reactive group for forming the linker moiety X, and Y is a labeling group.
-
- wherein R1 is a reactive group except an aminomethyl group, a hydroxymethyl group, an amino group, and a carboxyl group.
- According to the inventive labeling method, the phosphorylated peptide, namely, a protein can be easily detected. Thus, the present invention is useful in diagnosing diseases or the like with use of samples derived from living organisms or the like.
- Further, since the inventive compound (I) shows a unique coordination bond to the two hydroxy groups in a phosphoric monoester moiety or phosphoric ion, the inventive compound (I) is useful as a compound usable in the inventive method. Additionally, the inventive compound (I) is useful for purifying or concentrating phosphorylated peptide and obtaining the chemical information of phosphorylated peptide.
- These and other objects, features and advantages of the present invention will become more apparent upon reading of the following detailed description along with the accompanying drawings.
- FIG. 1 is an illustration showing a result of examination by an MALDI-TOF mass spectrometer regarding a zinc complex according to the present invention.
- FIG. 2 is an illustration showing electrophoresis gels, which is dyed by the inventive zinc complex (A) and further conventional dye (B). This illustration makes it clear that the inventive method can identify only phosphorylated peptide, while conventional method dyes all of the peptide.
- FIG. 3 is an illustration showing a result of examination by the MALDI-TOF mass spectrometer regarding a zinc complex according to the present invention, as well as an enlarged illustration showing a certain region of the examination result.
- FIG. 4 is an illustration showing a result of examination by the MALDI-TOF mass spectrometer regarding a zinc complex according to the present invention, as well as an enlarged illustration showing a certain region of the examination result.
- FIG. 5 is an illustration showing a result of examination by the MALDI-TOF mass spectrometer regarding the raw material compound used in producing the inventive compound having biotin as a labeling group, as well as an enlarged illustration showing a certain region of the examination result.
- FIG. 6 is an illustration showing a result of examination by the MALDI-TOF mass spectrometer regarding the raw material compound used in producing the inventive compound having biotin as a labeling group, as well as an enlarged illustration showing a certain region of the examination result.
- FIG. 7 is an illustration showing a result of examination by the MALDI-TOF mass spectrometer regarding a zinc complex according to the present invention, as well as an enlarged illustration showing a certain region of the examination result.
- FIG. 8 is an illustration showing a result of examination by the MALDI-TOF mass spectrometer regarding a zinc complex according to the present invention.
- FIG. 9 is an illustration showing electrophoresis gels, which is dyed by the inventive zinc complex (A) and further conventional dye (B). This illustration makes it clear that the inventive method can identify only phosphorylated peptide, while conventional method dyes all of the peptide.
- A primary feature of the inventive method resides in that a phosphorylated peptide can be easily identified by forming a composite compound in which a complex compound having a labeling group as represented by the formula (I) is specifically bonded to the phosphorylated peptide.
- There have been known various metallic complexes capable of being bonded to a phosphoric acid group. However, a compound which is analogous to the compound represented by the formula (I) and has a labeling group has been unknown. The inventors found that use of the complex compound represented by the formula (I) is advantageous in easily detecting and identifying a phosphorylated peptide even in a sample of a living organism containing a multitude of kinds of peptides, and accomplished the present invention.
- In the following, a method for labeling phosphorylated peptides according to an embodiment of the present invention is described
- First, prepared is a sample containing substantially all the possible kinds of peptides constituting a tissue cell to be examined. The preparation can be conducted according to a conventional method practiced in the biochemistry.
- Next, the peptides contained in the sample are separated. The separation method is not specifically limited, and a conventional separation method such as electrophoresis can be applied.
- In case of implementing the electrophoresis, the gel after the electrophoresis is immersed in a solution containing the complex compound represented by the formula (I) to label the phosphorylated peptide, and then, the phosphorylated peptide is detected by a detecting method depending on the kind of the labeling group.
- A solvent usable in the solution containing the complex compound represented by the formula (I) is not specifically limited, as far as the solvent does not hinder detection of the phosphorylated peptide. Water including a buffer and a solution containing a salt other than a buffer; alcohols such as methanol and ethanol; and a mixed solvent containing these components are examples of the solvent. Preferably, an aqueous solvent is used primarily for the purpose of preventing denaturation of the peptide.
-
- wherein X is a linker moiety, and Y is a labeling group.
- In the formula (I), Zn is selected as a coordinate metal because Zn is highly coordinated to a phosphoric acid group in a phosphorylated protein. namely, a phosphoric monoester moiety.
- The linker moiety in the present specification and the claims means a group capable of linking a main skeleton and a labeling group. The linker moiety facilitates production of the compound (I), and inhibits the labeling group from hindering coordination of the compound (I) to the phosphoric acid group bonded to the peptide. In view of this, the linker moiety may be a coordination bond which directly links the main skeleton and the labeling group if it is easy to obtain a raw material compound in which a labeling group is directly linked to a main skeleton in synthesizing the compound (I), or if the labeling group is of such a small size that hindrance of coordination of the compound (I) to the phosphoric acid group is securely prevented.
- The kind of the linker moiety in the present specification and the claims is not specifically limited, as far as the linker moiety has the above functions. Examples of the linker moiety are: a C1-C6 alkylene group, an amino group (—NH—), an ether group (—O—), a thioether group (—S—), a carbonyl group (—C(═O)—), a thionyl group (—C(═S)—), an ester group, an amide group, a urea group (—NHC(═O)NH—), a thiourea group (—NHC(═S)NH—); a C1-C6 alkylene group having, at one end thereof, a group selected from the group consisting of an amino group, an ether group, a thioether group, a carbonyl group, a thionyl group, an ester group, an amide group, a urea group, and a thiourea group; a C1-C6 alkylene group having, at the opposite ends thereof, two groups selected from the group consisting of an amino group, an ether group, a thioether group, a carbonyl group, a thionyl group, an ester group, an amide group, a urea group, and a thiourea group, wherein the groups at the opposite ends are identical to or different from each other; and a group in which two or more than two groups selected from the group consisting of an amino group, an ether group, a thioether group, a carbonyl group, a thionyl group, an ester group, an amide group, a urea group, a thiourea group, and a C1-C6 alkylene group are linearly linked.
- The C1-C6 alkylene group means a bivalent aliphathic hydrocarbon group having 1 to 6 carbon atoms of a straight chain or a branched chain, such as methylene, ethylene, propylene, tetramethylene, hexamethylene, methylethylene, methylpropylene, and dimethylpropylene, and preferably is a C1-C4 alkylene group, and more preferably is a C1-C2 alkylene group.
- The labeling group in the present specification and the claims is not specifically limited, as far as it is generally used in the biochemistry. However, a compound containing a radioisotope is not preferable in the aspect of handling. Examples of the labeling group are a fluorescent group, a group containing a nitro oxide radical and biotin.
- The fluorescent group is a substituent capable of stably generating fluorescence of a relatively long wavelength, and a group generally used in the biochemistry can be unlimitedly used as the fluorescent group, irrespective of the property that the compound is soluble in water or oil. Examples of the fluorescent group are aminomethylcoumarin and its derivatives, fluoroscein and its derivatives, tetramethylrhodamine and its derivatives, anthraniloyl and its derivatives, nitrobenzoxadiazole and its derivatives, and dimethylaminonaphthalene and its derivatives.
- The group containing a nitro oxide radical is a group having a stable radical, and is capable of detecting a phosphorylated peptide by electron spin resonance (ESR). Generally, a biological molecule does not show electron spin resonance because it does not have an unpaired electron. On the other hand, since a peptide bonded by the compound (I) having a nitro oxide radical being coordinated thereto shows electron spin resonance, the phosphorylated peptide is identifiable.
- Biotin has specific and high affinity to avidin derived from albumen and streptoavidin derived from actinomycetes. In view of this, the inventive complex compound can be specifically bonded to an enzyme by way of biotin and avidin or streptoavidin, by bonding avidin or streptoavidin to the inventive compound (I) having biotin as a labeling group and further bonding a biotinated enzyme. The phosphorylated peptide can be identified by using the enzyme such as alkaliphosphotase, peroxidase and luciferase, and by using a coloring reagent depending on the kind of the enzyme. For instance, if first phosphorylated peptide is bonded by the inventive complex compound, then the complex compound is bonded by alkaliphosphotase as the enzyme via streptoavidin, further nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate as the coloring reagents are added, and the mixture is reacted for several hours, the phosphorylated peptide turns into purple, thereby making it possible to identify the phosphorylated peptide. Further, streptoavdin labeled with a fluorescent pigment such as rhodamine is commercially available. Use of the streptoavidin labeled with the fluorescent pigment makes it possible to identify a phosphorylated peptide by a known fluorescent image analyzing method.
- Next, a method for selectively adsorbing phosphorylated peptides according to an embodiment of the present invention is described.
- According to the method for selectively adsorbing phosphorylated peptides, biotin or the like capable of specifically being bonded to a specific compound is used as a labeling group. For instance, an agarose gel with streptoavidin being bonded thereto is commercially available. An agarose gel with the inventive complex compound being bonded thereto can be obtained by applying the inventive complex compound having biotin as a labeling group to an agarose gel for reaction. The phosphorylated peptide in a mixed sample can be selectively adsorbed to the inventive complex compound by applying the mixed sample to the agarose gel. After the selective adsorption, adding a phosphoric acid buffer or the like capable of desorbing the phosphorylated peptide from the inventive complex compound makes it possible to obtain the phosphorylated peptide exclusively In this way, using the agarose gel is advantageous in purifying or concentrating a phosphorylated peptide without electrophoresis. Also, magnetic beads with streptoavidin being bonded thereto are commercially available. Use of the magnetic beads also makes it possible to purify or concentrate a phosphorylated peptide. Further, plates with streptoavidin being bonded thereto are commercially available for measuring surface plasmon resonance (SPR). A plate with the inventive complex compound being bonded thereto for measuring surface plasmon resonance can be obtained by applying the inventive complex compound having biotin as a labeling group onto the plate. Presence or absence of the phosphorylated peptide in a sample can be detected by measuring the surface plasmon resonance (SPR) of the plate.
- It is possible to synthesize a compound equivalent to the compound (I), in which a methyl group or the like is introduced to a pyridine ring, to provide substantially the same operations and effects as in the embodiment of the present invention. Such a compound equivalent to the compound (I) is embraced in the scope of the present invention.
-
- The compound (I) and the compound (I′) are substantially equivalent to each other. Although it is not clear as to which compound is synthesized, the compound (I) or the compound (I′), what is actually synthesized is conceivably a synthesized mixture of the compound (I) and the compound (I′). It is needless to say that the compound (I′) is embraced in the scope of the present invention.
-
- wherein X and Y is the same as defined above, and R1 and R2 each is a reactive group for forming the linker moiety X.
- In the above Scheme, the labeling group Y is introduced to the main skeleton via the linker moiety X by reacting the reactive groups R1 and R2.
- The kind of R1, R2, the solvent, a reaction temperature, a reagent other than the above, a purification method, and other factors are primarily determined by the kind of X. For instance, in case of introducing a labeling group via an amino group (a secondary or tertiary amino group), as a combination of R1 and R2, a combination of a group having an amino group (a primary or a secondary amino group) at a distal end thereof and a elimination group such as a halogen atom. Condensing R1 and R2 under the presence of basic groups in the solvent is an example of general reaction condition. In case that R1 is an active group, it is very easy to introduce a labeling group.
- Next, the compound (I) can be synthesized by adding a metallic salt to a solution containing the compound (IV). Zinc (II) nitrate or zinc (II) acetate may be added as the metallic salt. In case that zinc (II) acetate is added, a compound represented by the following formula (V) in which acetic acid is temporarily coordinated is produced.
- The compound (V) is chemically more stable than the compound (I), and accordingly useful in storage. The compound (V) is equivalent to the compound (I), and is usable in the similar manner as the compound (I). Specifically, by adding the compound (V) to the mixture containing the peptide, the phosphorylated peptide can be detected because the phosphoric monoester moiety is interchangeably coordinated to the compound (I) in place of the acetic acid.
-
- wherein R1 is the same as defined above, and “Hal” is a halogen atom, and preferably is a bromine.
- The compound (VI), i.e., 1,3-diamino-2-propanol, as a raw material compound may be commercially available. Further, since both the compound (VII) and the compound (IX) have a relatively simple structure, the compound (VII) and (IX) may be commercially available, or can be synthesized by a well-known method for a person skilled in the art.
- In
Scheme 2, first, the compound (VI) and the compound (VII) are reacted with each other under the presence of a catalyst for condensation to yield the compound (VIII). This reaction may be implemented step by step by introducing the compound (VII). Alternatively, the compound (VIII) can be obtained by a single step by using 3 or more equivalents of the compound (VII) to the compound (VI). - In
Scheme 2, reductive amination is carried out as a condensation reaction. A solvent used in the reductive amination is not specifically limited, as far as the solvent is capable of substantially dissolving the compound (VI) and the compound (VII), and does not inhibit the amination. For instance, alcohols such as methanol, ethanol and isopropanol; ethers such as diethyl ether, tetrahydrofuran and dioxane; water; or a mixed solvent containing two or more of these components can be used as the solvent. - The reductive amination can be carried out with use of a conventional reducing reagent after condensing the compound (VI) and the compound (VII) under the presence of concentrated hydrochloric acid, as a catalyst.
- An optimal condition regarding the reaction temperature and the reaction time can be optionally selected depending on the kind of the raw material compound or other factors. For example, the reaction may be carried out at a reaction temperature from 20 to 80° C. for a reaction time from 12 to 100 hours.
- After the reaction is completed, the solvent and the like are distilled off under depressurization before adding water. After water is added, the resultant mixture is extracted with a water-insoluble solvent, and the organic layer is dried over anhydrous magnesium sulfate or the like. Thereafter, the solvent is distilled off under depressurization. Subsequently, the residue is purified by a well known process such as silica gel column chromatography, thereby to yield the compound (VIII).
- The process for yielding the compound (VIII) is not limited to the process as shown by
Scheme 2. Alternatively, the compound (VIII) may be synthesized using the compound (VI) and a halogen compound, for example. - Next, the compound (II) can be synthesized by reacting the compound (VIII) with the compound (IX). This reaction can be carried out by a know process of synthesizing tertiary amines. For instances the compound (VIII) and the compound (IX) are condensed under the presence of base in a solvent. In the condensing step, a protective group may be introduced and cleaved depending on the kind of R1 according to needs. Alternatively, the compound (II) may be synthesized by implementing the condensing step with use of a compound having an inactive substituent group in place of using R1 in the compound (IX), and by substituting R1 for the inactive substituent group by functional group conversion. For instance, the condensing step is implemented by using a compound having a nitro group as the inactive substituent group and by substituting an amino group as the reactive group for the nitro group.
-
- wherein X, Y is the same as defined above, and R3 through R5 each is an electron donating substituent group at the 4 or 6 position on the pyridine ring.
- The complex compound (X) used in the inventive method is electrically enriched with pyridine nitrogen by the electron donating substituent group that has been introduced to an appropriate position for substitution. Accordingly, the complex compound (X) used in the inventive method is highly coordinated to zinc, thereby, making it possible to produce the complex compound (X) easily, while providing stability.
- A manner of using the complex compound (X), a process for producing the complex compound (X), and a raw materiel compound for the complex compound (X) are substantially the same as those regarding the complex compound (I).
- In the above methods and compound (I), it is preferable to use biotin, as the labeling group, in producing the complex compound. Use of biotin is preferred because biotin is easy to be handled, and has high usability in the point that it exhibits various colorings reactions. Use of biotin is effective in easily identifying the phosphorylated peptide.
- In the following, production examples and experiment examples are illustrated to describe the present invention in detail. The present invention is, however, not limited to the illustrated examples.
-
- To a solution of methyl 6-methylnicotinate (50 g, 331 mmol) in carbon tetrachloride (625 mL), was added N-bromosuccinimide (59 g, 331 mmol). Further 1.0 g of benzoyl peroxide was added, the mixture was reacted at a temperature from 40 to 50° C. for 24 hours with irradiation of light from a projector.
- After the reaction mixture was cooled, the precipitated crystals were separated by filtration. The filtrate was washed with an aqueous solution containing sodium hydrogencarbonate, and concentrated. The residue obtained by the concentration was purified by silica gel column chromatography, thereby to yield 37 g of the target compound.
-
-
- To a solution of 1,3-diaminopropane-2-ol (32.6 g, 362 mmol) in methanol (2400 mL), was added 60 mL of concentrated hydrochloric acid. Further 2-pyridine aldehyde (116.3 g, 1.09 mol) was added dropwise, and then sodium cyanoborohydride (50.16 g, 798 mmol) was added. After the addition was completed, the mixture was reacted at temperature for 3 days.
- After concentrated hydrochloric acid was added to the solution and the pH of the solution was adjusted to 6, the resulting solution was concentrated to some extent. Then, 0.1N aqueous solution of sodium hydroxide was added to adjust the pH of the solution to 7, followed by extraction with chloroform. The extracts were collected and dried, the resultant was concentrated. The residue obtained by the concentration was purified by silica gel column chromatography, thereby to yield 34 g of the target compound.
-
-
- N,N,N′-tri(2-pyridylmethyl)-1,3-diaminopropane-2-ol (18.2 g, 50 mmol) obtained in Production Example 1-2 in dried dimethylformamide (150 mL), was added potassium carbonate (13.8 g, 100 mmol), followed by addition of a solution of the methyl 6-bromomethylnicotinate (11.5 g, 50 mmol) obtained in Production Example 1-1 in dried dimethylformamide (75 mL) dropwise. After the dropwise addition was completed, the mixture was reacted at 50° C. for 1 hour.
- After the reaction was completed, the solution was cooled. Then, the cooled solution was poured into 750 mL of water, and the pH of the solution was adjusted to 8 by adding 1N hydrochloric acid. After extraction with ethyl acetate, the extracts were collected, washed with water and brine, and concentrated. The residue obtained by the concentration was purified by silica gel column chromatography, thereby to yield 21.5 g of the target compound.
-
-
- N,N,N′-tri(2-pyridylmethyl)-N′-(5-methoxycarbonyl-2-pyridylmethyl)-1,3-diaminopropane-2-ol (9.7 g, 18.9 mmol) obtained in Production Example 1-3 in methanol (100 mL), was added ethylenediamine (22.7 g, 378 mmol) dropwise. After the dropwise addition, the mixture was reacted at room temperature for 3 days.
- After the reaction was completed, the solution was concentrated, and the residue obtained by the concentration was purified by silica gel column chromatography, thereby to yield 9.72 g of the target compound.
-
-
- N,N,N′-tri(2-pyridylmethyl)-N′-[5-N″-(2-aminoethyl)carbamoyl-2-pyridylmethyl]-1,3-diaminopropane-2-ol (200 mg, 0.37 mmol) obtained in Production Example 1-4 in acetonitrile (20 mL), was added sodium hydrogencarbonate (336 mg, 4.0 mmol), followed by addition of 4-chloro-7-nitro-2,1,3-benzoxadiazole (73.8 mg, 0.37 mmol). The mixture was reacted at room temperature for 2 hours.
- After the reaction was completed, the solution was concentrated. Then, 50 mL of dichloromethane and 50 mL of water were added, and the organic layer and aqueous layer were separated. The organic layer was dried over anhydrous sodium sulfate, concentrated, and the obtained residue was purified by silica gel column chromatography, thereby to yield 71.2 mg of the target compound.
-
-
- Prepared was 50 μM aqueous solution containing the compound obtained in Production Example 1-5, followed by addition of zinc nitrate of 2 equivalents to the solution. Thus, a solution containing the inventive zinc complex was prepared.
- The zinc complex was identified according to the following method. Specifically, the compound obtained in Production Example 1-5 was dissolved in a phosphoric acid buffer (pH=6.86) to obtain the 50 μM solution, followed by addition of zinc nitrate of 2 equivalents to the solution. The inventive zinc complex in the solution exhibits the following structure, and was identified by MALDI-TOF mass spectrometer (Matrix: 2′,4′,6′-trihydroxyacetophenone, Mode: reflector, Accelerating Voltage: 20000V, Grid Voltage: 57.500%, Laser: 2500, Scans Averaged: 128, Pressure: 5.05e-07).
- The result of measurement by the MALDI-TOF mass spectrometer is shown in FIG. 1. As shown in FIG. 1, a molecular ion peak at 926.2 (exact mass: 926.11) was observed. It is considered that a molecular ion peak at 910.2 appeared because the oxygen in the oxadiazole group was eliminated.
-
- To a solution of D-biotin (137 mg, 0.56 mmol) in dimethylformamide (10 mL), was added 1,1′-carbonyldiimidazole (116 mg, 0.72 mmol). The mixture was reacted at room temperature for 12 hours. Thereafter, the solution was cooled with ice, followed by dropwise addition of a solution of N,N,N′-tri(2-pyridylmethyl)-N′-[5-N″-(2-aminoethyl)carbamoyl-2-pyridylmethyl]-1,3-diaminopropane-2-ol (260 mg, 0.48 mmol) obtained in Production Example 1-4 in dimethylformamide (3 mL). The cooling bath was detached, and the reaction was carried out at room temperature for 2 hours.
- After the reaction was completed, the solution was poured into 50 mL of water, followed by extraction with 50 mL of chloroform twice. After the extracts were concentrated, the crude product was purified by silica gel column chromatography, thereby to yield 265 mg of the target compound
-
-
- The compound obtained in Production Example 2-1 was dissolved in a phosphoric acid buffer (pH=6.86) to obtain 3 mM solution, followed by addition of zinc nitrate of 2 equivalents to the solution.
-
- A result of measurement by the MALDI-TOF mass spectrometer is shown in FIG. 3. As shown in FIG. 3, a molecular ion peak at 989.6 (exact mass: 989.19) is observed.
- First, prepared were gels for electrophoresis, a pH buffer for electrophoresis, and a coloring solution for dissolving samples under the following conditions.
- Stacking gel;
- 125 mM of Tris-hydrochloric acid buffer (pH=6.8)
- 4.5% (w/v) of polyacrylamide (acrylamide:bisacrylamide=30:1)
- Separation gel:
- 375 mm of Tris-hydrochloric acid buffer (pH=8.8)
- 10% (w/v) of polyacrylamide (acrylamide:bisacrylamide=30:1)
- pH buffer for electrophoresis (pH=8.3):
- 25 mM of Tris
- 190 mM of glycine
- Coloring solution for dissolving samples (3-times concentrated solution):
- 195 mM of Tris-hydrochloric acid buffer (pH=6.8)
- 10% (w/v) of glycerol
- 0.1% (w/v) of bromo phenol blue (BPB), as a coloring marker used in electrophoresis
- Next, 2 μg each of 1: Bovine Serum Albumin, 2: β-casein (phosphorylated), and 3: β-casein (de-phosphorylated) was dissolved in the coloring solution to prepare samples. The respective samples were plotted on the gel. Then, a constant electric current of 4 mA was applied until the coloring marker was flowed out.
- The gel was immersed in the zinc-complex-containing solution (50 μM) obtained in Production Example 1-6 for about 30 minutes. Then, the gel was taken out from the solution, and photographed under irradiation by a UV lamp. Further, the gel was dyed with Coomassie brilliant blue according to a conventional dying process, and the dyed gel was photographed. The gel dyed with the zinc-complex-containing solution is referred to as “gel A”, and the gel dyed with Coomassie brilliant blue is referred to as “gel B”, both of which are shown in FIG. 2.
- As is obvious from FIG. 2, according to the inventive method, β-casein being bonded with phosphoric acid can be identified exclusively. Thus, it is clear that the inventive method is advantageous in identifying phosphorylated peptide exclusively in samples derived from living organisms.
-
- N,N,N′-tri(2-pyridylmethyl)-N′-[5-N″-(2-aminoethyl)carbamoyl-2-pyridylmethyl]-1,3-diaminopropane-2-ol (113 mg, 0.21 mmol) obtained in Production Example 1-4 in acetonitrile (10 mL), was added a solution of 5-(N-succineimidyloxycarbonyl)pentyl-D-biotinamide (95 mg, 0.21 mmol) in dimethylsulfoxide (2 mL) dropwise.
- After the mixture was reacted at room temperature for 6 hours, the reaction mixture was concentrated, and the crude product obtained by the concentration was purified by silica gel column chromatography, thereby to yield 136 mg of a target compound (yield: 76%).
-
-
-
- To a phosphoric acid buffer (pH=6.86), dissolved was 200 nmol of the compound obtained in Production Example 3-1 to prepare 3 mM solution containing the compound, followed by addition of zinc nitrate of 2 equivalents to the solution. Thus, a solution containing the inventive zinc complex was prepared.
- The solution was analyzed by the MALDI-TOF mass spectrometer (matrix: 2′,4′,6′-trihydroxyacetophenone), and the zinc complex was identified. A result of measurement by the MALDI-TOF mass spectrometer is shown in FIG. 4. As shown in FIG. 4, a molecular ion peak at 1102.3 (exact mass: 1102.27) was observed.
- The suspension (0.3 mL) containing Streptavidin agarose (quantity of the bonded moiety of biotin: 60 to 120 nmol/mL) and a buffer (Sigma-Aldrich Co.) was charged in a centrifugal filter unit (volume: 0.5 mL filter pore diameter: 0.22 μm). The filter unit was subjected to centrifugal separation at centrifugal acceleration of 2,000×g for 15 seconds, followed by filtration of the suspension. 5.0 mM Tris-acetate buffer (pH=7.4, 0.30 mL) was charged in the filter unit, then the filter unit was subjected to centrifugal separation at 2,000×g for 15 seconds and filtration for washing. This centrifugal separation and filtration step for washing was cyclically repeated for 5 times.
- To the filter unit, charged was 5.0 mM Tris-acetate buffer (pH=7.4, 0.30 mL) dissolving 120 nmol/mL of the compound obtained in Production Example 3-1 and 500 nmol/mL of zinc acetate. The filter unit was brought to an equilibrium state for 5 minutes, and then, subjected to centrifugal separation at 2,000×g for 15 seconds and filtration. Next, 5.0 mM Tris-acetate buffer (pH=7.4, 0.30 mL) was charged in the filter unit, and subjected to centrifugal separation at 2,000×g for 15 seconds and filtration for washing. This centrifugal separation and filtration step for washing was cyclically repeated for 5 times. Further, 5.0 mM Tris-acetate buffer (pH=7.4, 0.30 mL) dissolving 10 nmol/mL of zinc acetate was charged in the filter unit, and subjected to centrifugal separation at 2,000×g for 15 seconds and filtration for washing. This centrifugal separation and filtration step for washing was cyclically repeated for 5 times.
- To the filter unit, charged was 5.0 mM Tris-acetate buffer (pH=7.4, 0.30 mL) dissolving non-phosphorylated peptide p60c (p60c-src peptide 521-533, 14 nmol/mL) and phosphorylated peptide P-p60c (O-phosphoryl p60c-src peptide 521-533, 12 nmol/mL), as samples. The filter unit was brought to an equilibrium state for 5 minutes, and then, subjected to centrifugal separation at 2,000×g for 15 seconds and filtration. The obtained filtrate was taken out as a
fraction 1. - Next, 5.0 mM Tris-acetate buffer (pH=7.4, 0.50M NaNO3, 0.30 mL) was charged in the filter unit, and the filter unit was subjected to centrifugal separation at 2,000×g for 15 seconds and filtration for 3 times. The filtrate obtained after the first filtration was taken out as a
fraction 2, the filtrate after the second filtration was taken out as afraction 3, and the filtrate after the third filtration was taken out as afraction 4. - Furthermore, 1.0 mM buffer containing phosphoric acid-sodium hydroxide (pH=7.4, 0.50M NaNO3, 0.30 mL) was charged in the filter unit, and the filter unit was subjected to centrifugal separation at 2,000×g for 15 seconds and filtration for 2 times. The filtrate obtained after the first filtration was taken out as a
fraction 5, and the filtrate after the second filtration was taken out as afraction 6. - The contents of the peptide in the
respective fractions 1 through 6 were quantitatively determined by high performance liquid chromatography (HPLC). The isolation/recovery rates of the respective peptides to the total amount are shown in Table 1.TABLE 1 Fraction No. 1 2 3 4 5 6 p60c (%) 67 24 9 0 0 0 P-p60c (%) 0 0 0 0 83 17 - Analyzing conditions according to HPLC:
- column: Capcell Pak C18 type UG80, 4.6 mm (diameter)×150 mm mobile phase: acetonitrile:water=14:86(v/v), 0.1%(v/v) of trifluoroacetic acid
- flow rate: 1 mL/min.
- column temperature: 40° C.
- detecting method: UV 266 nm
- retention time: P-p60c (5.3 min.). p60c (13.4 min.)
- The above results reveal that the inventive complex compound can adsorb selectively a phosphorylated peptide and use of the inventive complex compound is advantageous in selectively isolating the phosphorylated peptide in a mixed sample of the phosphorylated peptide and the non-phosphorylated peptide.
- The suspension (0.3 mL) containing Streptavidin agarose (quantity of the bonded moiety of biotin; 60 to 120 nmol/mL) and a buffer (Sigma-Aldrich Co.) was charged in a centrifugal filter unit (volume: 0.5 mL, filter pore diameter: 0.22 μm). The filter unit was subjected to centrifugal separation at 2,000×g for 15 seconds, followed by filtration of the suspension. Then, 5.0 mM Tris-acetate buffer (pH=7 4, 0.30 mL) was charged in the, filter unit, and the filter unit was subjected to centrifugal separation at 2,000×g for 15 seconds and filtration for washing. This centrifugal separation and filtration step for washing was cyclically repeated for 5 times.
- A process similar to the process in Experiment Example 2 was conducted with use of samples equivalent to the samples used in Experimental Example 2, using a filter unit (in this Comparative Example, the inventive complex compound was not included). Thus,
fractions 7 through 12 were obtained. - HPLC analysis was conducted with respect to the
fractions 7 through 12 in a similar manner as Experimental Example 2. Results of the analysis are shown in Table 2.TABLE 2 Fraction No. 7 8 9 10 11 12 p60c (%) 75 20 5 0 0 0 P-p60c (%) 83 17 0 0 0 0 - The results in Table 2 reveal that separation of the phosphorylated peptide from the non-phosphorylated peptide is unsuccessful, even if a process similar to the process in Experimental Example 2 is conducted, because the inventive complex compound is not used.
-
- 200 mL of acetic anhydride was heated to 100° C., followed by gradual addition of 2-methyl-4-nitropyridine N-oxide (25.0 g, 162 mmol). After the addition, the mixture was gradually heated, and was kept at 130° C. for 20 minutes. Then, the reaction mixture was cooled to 80° C., followed by dropwise addition of 200 mL of ethanol to stop the reaction.
- After the reaction mixture was concentrated, the residue was put in water of 500 mL, and the pH of the mixture was adjusted to 9 by adding sodium hydrogencarbonate. After extraction with ethyl acetate twice (500 mL in the first extraction, and 200 mL in the second extraction), the obtained organic layers ware washed with 200 mL of water and 200 mL of brine. After concentration of the organic layer, the obtained crude product was purified by silica gel column chromatography, thereby to yield 7.68 g of the target compound.
-
-
- To 2-acetoxymethyl-4-nitropyridine (7.68 g, 39.2 mmol) obtained in Production Example 4-1, added was 30 mL of 10% hydrochloric acid. The mixture was reacted at 50° C. for 30 minutes. After the reaction mixture was cooled, the solution was poured into 200 mL of water, and the pH of the mixture was adjusted to 9 by adding sodium hydrogencarbonate. The mixture was extracted with 100 mL of ethyl acetate for three times, and the obtained organic layers were concentrated. The residue obtained by the concentration was purified by silica gel column chromatography, thereby to yield 4.70 g of the target compound.
-
-
- To a suspension of 2-hydroxymethyl-4-nitropyridine (1.00 g, 6.49 mmol) obtained in Production Example 4-2 in dried ether (40 mL), was added phosphorus tribromide (0.88 g, 3.24 mmol) at 0° C. dropwise. After the dropwise addition, the mixture was reacted at 0° C. for 2 hours, followed by reaction at 20° C. for 64 hours.
- The reaction mixture was poured into 250 mL of ice-cold water, and the pH of the aqueous layer was adjusted to 8 by adding sodium hydrogencarbonate. After the ether layer and the aqueous layer were separated, the aqueous layer was extracted with 100 mL of ethyl acetate twice. The organic layers were collected, and dried over anhydrous sodium sulfate. After the solvent was distilled off, the crude product was purified by silica gal column chromatography, thereby to yield 0.80 g of the target compound.
-
-
- N,N,N′-tri(2-pyridylmethyl)-1,3-diaminopropane-2-ol (2.65 g, 7.28 mmol) obtained in Production Example 1-2 in dried dimethylformamide (40 mL), was added anhydrous potassium carbonate (2.02 g, 14.6 mmol), and the mixture was heated to 55° C. Then, a solution of the 2-bromomethyl-4-nitropyridine (1.58 g, 7.28 mmol) obtained in Production Example 4-3 in dried dimethylformamide (20 mL) was added dropwise at the same temperature, i.e., 55° C. After the mixture was reacted at 55° C. for 1.5 hours, the mixture was cooled.
- The reaction mixture was poured into 200 mL of water, and the pH of the mixture was adjusted to 8 by adding 1N hydrochloric acid. After extraction with 400 mL of ethyl acetate for three times, the organic layer was washed with 250 mL of brine. After being dried over anhydrous magnesium sulfate, the organic layer was concentrated. After the solvent was distilled off, the crude product was purified by silica gel column chromatography, thereby to yield 3.30 g of the target compound.
-
-
- N,N,N′-tri(2-pyridylmethyl) -N′-(4-nitro-2-pyridylmethyl)-1,3-diaminopropane-2-ol (1.01 g, 2.00 mmol) obtained in Production Example 4-4 in dried tetrahydrofuran (17 mL), was added sodium azide (156 mg, 2.40 mmol) in water (3.3 mL) dropwise at room temperature. The reaction mixture was heated to 50° C., and reacted at the same temperature, i.e., 50° C. for 17 hours.
- After the mixture was cooled, the aqueous layer was extracted with 10 mL of chloroform twice. The extracts were collected and concentrated, and the resulting crude product obtained was purified by silica gel column chromatography, thereby to yield 980 mg of the target compound.
-
-
- N,N,N′-tri(2-pyridylmethyl)-N′-(4-azide-2-pyridylmethyl)-1,3-diaminopropane-2-ol (980 mg, 1.98 mmol) obtained in Production Example 4-5 in ethanol (20 mL), was added 100 mg of platinum oxide. The mixture was reacted under hydrogen pressure of 30 kPa for 2 hours. After the catalyst (platinum oxide) was removed by filtration, the filtrate was concentrated, and the resulting crude product was purified by silica gel column chromatography, thereby to yield 690 mg of the target compound.
-
-
- 62.4 mg of D-biotin (0.26 mmol) was suspended into 5 mL of dichloromethane, followed by addition of 5.2 mg of 4-dimethylaminopyridine (0.04 mmol) and 35.8 μL of triethylamine (0.26 mmol) at room temperature. To this mixture, was added a solution of N,N,N′-tri(2-pyridylmethyl)-N′-(4-amino-2-pyridylmethyl)-1,3-diaminopropane-2-ol (100 mg, 0.21 mmol) obtained in Production Example 4-6 in dichloromethane (2 mL) dropwise at room temperature. After the dropwise addition, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (49.0 mg, 0.26 mmol) was added at room temperature. The reaction mixture was heated, and reacted under reflux for 5 hours. To the reaction mixture, were added D-biotin (6.0 mg, 0.02 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (10.0 mg, 0.05 mmol), and 2 mL of dichloromethane, followed by reaction under reflux for 6 hours.
- After the reaction mixture cooled, the mixture was poured into 40 mL of water. After extraction with 30 mL of chloroform for three times, the organic layers were washed with 30 mL of water twice and 30 mL of brine. After the organic layer was dried over anhydrous magnesium sulfate and concentrated, the resulting crude product was purified by HPLC, thereby to yield 62.5 mg of the target compound.
-
- This compound was examined by the MALDI-TOF mass spectrometer using α-cyano-4-hydroxycinnamic acid (CHCA) as a matrix. A result of measurement is shown in FIG. 5. As is obvious from FIG. 5, a molecular ion peak 696.2 of proton adduct ion (M++1) was observed.
-
- To a suspension of 6-aminohexanoic acid (10.0 g, 76.2 mmol) in methanol (300 mL), was added 5.51 g of concentrated sulfuric acid. The mixture was heated and reacted for 8 hours, while the water formed along with the progress of esterification distilled off with methanol and 60 mL of methanol was added four times on cue. The reaction mixture was cooled, and the pH of the mixture was adjusted to 6.2 by adding 28% methanol solution of sodium methoxide. The solvent was distilled off, the residue was added to 500 mL of water, and the pH of the mixture was adjusted to 10.3 by adding sodium carbonate. After extraction with 350 mL of dichloromethane for three times, the extract was dried over anhydrous magnesium sulfate. Thereafter, the solvent was distilled off, thereby to yield methyl 6-aminohexanoate.
- The methyl 6-aminohexanoate was dissolved in 40 mL of dioxane, followed by addition of 7.1 mL of 4N-hydrochloride solution of dioxane. After the mixture was stirred at room temperature for 30 minutes, the solvent was distilled off, followed by addition of ether to the residue. The precipitated crystals were isolated by filtration and dried under reduced pressure to yield 3.3 g of the target compound.
-
-
- To a solution of methyl 6-aminohexanoate hydrochloride (1.00 g, 5.50 mmol) obtained in Production Example 5-1 in dimethylformamide (40 mL), were added triethylamine (1.20 g, 11.8 mmol) and 4-dimethylaminopyridine (137 mg, 1.1 mmol). Furthermore, were added D-biotin (1.34 g, 5.50 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.42 g, 7.42 mmol) The mixture was reacted at temperature from 35 to 45° C. for 23 hours.
- The reaction mixture was poured into 300 mL of water, and extracted with 150 mL of chloroform for 5 times. After the extracts were dried over anhydrous magnesium sulfate and the solvent was distilled off. The resulting crude product was purified by silica gel column chromatography, thereby to yield 1.04 g of the target compound.
-
-
- To a mixture of 25 mL of tetrahydrofuran and 25 mL of methanol, was dissolved 5-carbomethoxypentyl-D-biotinamide (800 mg, 2.15 mmol) obtained in Production Example 5-2, followed by addition of a solution of sodium hydroxide (2.33 g, 58.3 mmol) in water (12.5 mL) dropwise at room temperature. After the addition was completed, the mixture was heated to 40° C. and reacted for 2 hours.
- After cooling, the reaction mixture was concentrated, followed by addition of 60 mL of water. Then, 1N hydrochloric acid was added, and the pH of the mixture was adjusted to 2.0. The precipitated crystals were isolated by filtration and washed with water. The obtained crystals were dried in vacuo, thereby to yield 724 mg of the target compound.
-
-
- To a solution of 5-carboxypentyl-D-biotinamide (99.0 mg, 0.27 mmol) obtained in Production Example 5-3 in dried dimethylformamide, were added triethylamine (38.1 μL, 0.27 mmol) and 4-dimethylaminopyridine (5.7 mg, 0.04 mmol), followed by addition of a solution of N,N,N′-tri(2-pyridylmethyl)-N′-(4-amino-2-pyridylmethyl)-1,3-diaminopropane-2-ol (100 mg, 0.21 mmol) obtained in Production Example 4-6 in dried dimethylformamide (1 mL) dropwise. Further, was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (51.7 mg, 0.27 mmol). The mixture was reacted at 40° C. for 24 hours. To the reaction mixture, added were 8.9 μL of triethylamine (0.06 mmol), 22.8 mg of 5-carboxypentyl-D-biotinamide (0.06 mmol) and 12.2 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.06 mmol). The mixture was reacted at 40° C. for 6 hours.
- After the reaction mixture was cooled, the mixture was poured into 150 mL of water, followed by addition of sodium chloride to attain saturation. After extraction with 40 mL of chloroform for 5 times, the organic layers were washed with 150 mL of water twice and 150 mL of brine. After extract was dried over anhydrous magnesium sulfate, the solvent was distilled off. The crude product obtained was purified by HPLC, thereby to yield 37.5 mg of the target compound.
-
- This compound was measured by the MALDI-TOF mass spectrometer using CHCA as a matrix. A result of measurement is shown in FIG. 6. As is obvious from FIG. 6, a molecular ion peak 809.5 of proton adduct ion (M++1) was observed
-
- To 25% acetic acid solution of hydrogen bromide (12.8 g, 39.6 mmol), was added 3-hydroxy-2-hydroxymethylpyridine hydrochloride (5.0 g, 54.7 mmol). The mixture was reacted at 110° C. for 1 hour. Furthermore, was added 25% acetic acid solution of hydrogen bromide (4.90 g, 15.1 mmol) dropwise, and the mixture was reacted for 2 hours.
- After cooling, the reaction mixture was poured into 50 mL of water, and the pH of the mixture was adjusted to 8 by adding saturated aqueous sodium hydrogencarbonate solution. After extraction with 50 mL of dichloromethane for four times, the dichloromethane layers were concentrated. The crude product after the concentration was purified by silica gel column chromatography, thereby to yield 1.36 g of the target compound.
-
-
- In dimethylformamide (15 mL), were dissolved N,N,N′-tri(2-pyridylmethyl)-1,3-diaminopropane-2-ol (1.00 g, 2.75 mmol) obtained in Production Example 1-2 and 2-bromomethyl-3-hydroxypyridine (633 mg, 3.37 mmol) obtained in Production Example 6-1 , followed by addition of potassium carbonate (760 mg, 5.50 mmol). The mixture was reacted at 50° C. for 2 hours and cooled.
- The reaction mixture was poured into 100 mL of water, and the pH of the mixture was adjusted to 8 by adding 1N hydrochloric acid. After extraction with 100 mL of ethyl acetate for three times, the organic layers were washed with 100 mL of water and 100 mL of brine, and dried over anhydrous sodium sulfate. The obtained crude product was purified and collected by HPLC, thereby to yield 660 mg of the target compound.
-
-
- N,N,N′-tri(2-pyridylmethyl)-N′-(3-hydroxy-2-pyridylmethyl)-1,3-diaminopropane-2-ol (100 mg, 0.21 mmol) obtained in Production Example 6-2 in dried dimethylformamide (5 mL), was added sodium hydride (dispersion in mineral oil) (9.0 mg, 0.23 mmol) at 3° C. After the temperature was returned to room temperature, the mixture was reacted at room temperature for 30 minutes, followed by addition of a solution of N-succinimidyl D-biotinate (79.8 mg, 0.23 mmol) in dried dimethylsulfoxide (1 mL) dropwise.
- After the dropwise addition, the mixture was reacted at room temperature for 3.5 hours and poured into 100 mL of water. After extraction with 300 mL of chloroform for three times, the chloroform layers were dried over anhydrous sodium sulfate. After the solvent was distilled off, the crude product was collected and purified by HPLC, thereby to yield 63.6 mg of the target compound.
-
-
- To an acetonitrile solution (66.7 μL) containing 200 nmol of N,N,N′-tri(2-pyridylmethyl)-N′-(3-D-biotinyloxy-2-pyridylmethyl)-1,3-diaminopropane-2-ol obtained in Production Example 6-3, added was 40.1 μL of 100 mM zinc nitrate aqueous solution, followed by addition of 560 μL of phosphoric acid buffer (pH=6.86). The solution was analyzed by the MALDI-TOF mass spectrometer by using 2′,4′-6′-trihydroxyacetophenone (THAP) as a matrix, and the zinc complex was identified. A result of measurement by the MALD-TOF mass spectrometer is shown in FIG. 7. As shown in FIG. 7, a molecular ion peak at 919.1 (exact mass: 919.13) was observed.
-
- In dried acetonitrile (9 mL), was dissolved N,N,N′-tri(2-pyridylmethyl)-N′-[5-N″-2-(aminoethyl)carbamoyl-2-pyridylmethyl]-1,3-diaminopropane-2-ol (1.1 g, 2.1 mmol) obtained in Production Example 1-4, followed by addition of dansyl chloride (840 mg, 3.1 mmol). The reaction mixture was heated and reacted at 50° C. for 3 hours. After the reaction mixture was concentrated, the crude product was purified by silica gel column chromatography, thereby to yield 1.30 g of the target compound.
-
-
-
- In a phosphoric acid buffer (pH=6.86), dissolved was 200 nmol of N,N,N′-tri(2-pyridylmethyl)-N′-[5-N″-(2-dansylaminoethyl)carbamoyl-2-pyridylmethyl]-1,3-diaminopropane-2-ol obtained in Production Example 7-1 to prepare 3 mM solution, followed by addition of zinc nitrate of 2 equivalents to the solution. The solution was analyzed by the MALDI-TOF mass spectrometer by using THAP as a matrix, and the zinc complex was identified. A result of measurement by the MALDI-TOF mass spectrometer is shown in FIG. 8. As shown in FIG. 8, a molecular ion peak at 996.2 (exact mass: 996.16) was observed.
-
- In dried dimethylformamide (150 mL), was dissolved N,N,N′-tri(2-pyridylmethyl)-N′-[5-N″-(2-aminoethyl)carbamoyl-2-pyridylmethyl]-1,3-diaminopropane-2-ol (950 mg, 1.76 mmol) obtained in Production Example 1-4, followed by addition of dried pyridine (38 mL). Then, a solution of fluorescein-5-isothiocyanate (750 mg, 1.92 mmol) in dried dimethylformamide (150 mL) was added dropwise, and the mixture was reacted at room temperature for 3 hours. After the reaction mixture was concentrated, the crude product was purified by silica gel column chromatography, thereby to yield 961 mg of the target compound.
-
- First, prepared were gels for electrophoresis, pH buffer for electrophoresis, and a coloring solution for dissolving samples under the same condition as in Experimental Example 1.
- Next, 2 μg each of 1: Bovine Serum Albumin, 2: Human Serum Albumin, 3: carbonic anhydrase, 4: β-galactosidase, 5: α-casein (phosphorylated), 6: α-casein (de-phosphorylated), 7: β-casein (phosphorylated), 8: β-casein (de-phosphorylated), 9: pepsin (phosphorylated), and 10: pepsin (de-phosphorylated) was dissolved in the coloring solution to prepare samples. The respective samples were plotted on the gel. Then, a constant electric current of 40 mA was applied until the coloring marker was flowed.
- The obtained gel was immersed in a 10 mM Tris-acetate buffer (pH=7.4) containing 1 μM of N,N,N′-tri(2-pyridylmethyl)-N′-[5-N″-(2-N-5-fluoresceinylthioureidoethyl)carbamoyl-2-pyridylmethyl]-1,3-diaminopropane-2-ol obtained in Production Example 8-1 and 100 μM zinc acetate for 30 minutes. Thereafter, the gel was taken out from the solution. This gel was washed with 100 mL of 10 mM Tris-acetate buffer (pH=7.4) for 10 minutes twice. Thereafter, a fluorescent image of the gel was photographed by using a fluoro image analyzer FLA-5000 (Fuji Photo Film Co., Ltd.) at an excitation wavelength of 473 nm with use of a fluorescence detecting filter of 510 nm. Then, the gel was dyed with Coomassie brilliant blue according to a conventional dying process, and the dyed gel was photographed. The gel dyed with the zinc-complex-containing solution is referred to as “gel A”, and the gel dyed with Coomassie brilliant blue is referred to as “gel B”, both of which are shown in FIG. 9.
- As is obvious from FIG. 9, in case that being dyed according to the conventional dyeing process, all the peptides were dyed as shown by the gel B. On the other hand, only 5: α-casein (phosphorylated), 7: β-casein (phosphorylated) and 9: pepsin (phosphorylated) to all of which the phosphoric acid has been bonded were identified exclusively, as shown by the gel A which was treated with the solution containing the inventive zinc complex. Thus, it is clear that the inventive method is advantageous in determining phosphorylated peptides exclusively in samples derived from living organisms.
- This application is based on Japanese Patent Application No. 2003-56068 filed on Mar. 3, 2003, No. 2003-113707 filed on Apr. 18, 2003 and No. 2003-356934 filed on Oct. 16, 2003, the contents of which are hereby incorporated by references.
- Although the present invention has been fully described by way of example, it is to be understood that various changes and modifications will be apparent to those skilled in the art. Therefore, unless otherwise such changes and modifications depart from the scope of the present invention hereinafter defined, they should be construed as being included therein.
Claims (8)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-56068 | 2003-03-03 | ||
JP2003056068 | 2003-03-03 | ||
JP2003-113707 | 2003-04-18 | ||
JP2003113707 | 2003-04-18 | ||
JP2003356934 | 2003-10-16 | ||
JP2003-356934 | 2003-10-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20040198712A1 true US20040198712A1 (en) | 2004-10-07 |
US7202093B2 US7202093B2 (en) | 2007-04-10 |
Family
ID=32830641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/784,576 Active 2024-09-26 US7202093B2 (en) | 2003-03-03 | 2004-02-23 | Method for labeling phosphorylated peptides, method for selectively adsorbing phosphorylated peptides, complex compounds used in the methods, process for producing the complex compounds, and raw material compounds for the complex compounds |
Country Status (9)
Country | Link |
---|---|
US (1) | US7202093B2 (en) |
EP (1) | EP1455189B1 (en) |
CN (1) | CN100344647C (en) |
AT (1) | ATE464566T1 (en) |
AU (1) | AU2004218127B2 (en) |
CA (1) | CA2517705C (en) |
DE (1) | DE602004026500D1 (en) |
TW (1) | TW200502238A (en) |
WO (1) | WO2004078724A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050269267A1 (en) * | 2004-03-19 | 2005-12-08 | Perkinelmer Las, Inc. | Separations platform based upon electroosmosis-driven planar chromatography |
WO2006014424A2 (en) | 2004-07-06 | 2006-02-09 | Perkinelmer Las, Inc. | Methods and compositions for detecting and isolating phosphorylated molecules using hydrated metal oxides |
US20060183237A1 (en) * | 2003-03-07 | 2006-08-17 | Kabushiki Kaisha Nard Kenkyusho | Method of measuring the molecular weight of phoshoric acid monoester compound and additive for mass spectrum measurement |
US20070161030A1 (en) * | 2005-12-08 | 2007-07-12 | Perkinelmer Las, Inc. | Micelle-and microemulsion-assisted planar separations platform for proteomics |
US20070187243A1 (en) * | 2005-11-10 | 2007-08-16 | Perkinelmer Life And Analytical Sciences | Planar electrochromatography/thin layer chromatography separations systems |
US20070251824A1 (en) * | 2006-01-24 | 2007-11-01 | Perkinelmer Las, Inc. | Multiplexed analyte quantitation by two-dimensional planar electrochromatography |
US20070287161A1 (en) * | 2006-04-28 | 2007-12-13 | Patton Wayne F | Detecting Phospho-Transfer Activity |
US20080064608A1 (en) * | 2004-07-13 | 2008-03-13 | Toyo Boseki Kabushiki Kaisha | Method Of Detecting Phosphorylation By Spr Using Zinc Chelating Reagent |
US20090185181A1 (en) * | 2003-10-24 | 2009-07-23 | Kabushiki Kaisha Nard Kenkyusho | Method for measuring a surface plasmon resonance and noble metal compound used for the same |
US20100099120A1 (en) * | 2005-08-09 | 2010-04-22 | Tohru Koike | Method for staining substances having a phosphate group |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2542742C (en) * | 2003-10-16 | 2015-04-21 | Kabushiki Kaisha Nard Kenkyusho | Method for measuring a surface plasmon resonance and noble metal compound used for the same |
WO2007015312A1 (en) * | 2005-08-01 | 2007-02-08 | Nard Institute, Ltd. | Polyacrylamide gel for electrophoresis, polyacrylamide gel electrophoresis method using the same, method of producing the same and acrylamide compound |
US7454882B2 (en) * | 2006-10-12 | 2008-11-25 | Bowe Bell + Howell Company | Methods for variably opening envelopes |
CN101288844B (en) * | 2007-04-20 | 2011-04-20 | 中国科学院大连化学物理研究所 | Affinity chromatography fixed phase of immobilization metal and its preparation method |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874584A (en) * | 1993-04-21 | 1999-02-23 | Eastman Kodak Company | Ion-sensitive compounds |
US6120768A (en) * | 1993-05-17 | 2000-09-19 | Immunomedics, Inc. | Dota-biotin derivatives |
US6143879A (en) * | 1994-01-14 | 2000-11-07 | Regents Of The University Of Minnesota | Nucleotide cleaving agents and method |
US20050038258A1 (en) * | 2001-12-21 | 2005-02-17 | Tohru Koike | Zinc complexes capable of capturing substances having anionic substituents |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001253871A (en) | 2000-03-10 | 2001-09-18 | Japan Science & Technology Corp | Receptor compound for protein or peptide |
-
2004
- 2004-02-23 WO PCT/JP2004/002048 patent/WO2004078724A1/en active Application Filing
- 2004-02-23 AU AU2004218127A patent/AU2004218127B2/en not_active Expired
- 2004-02-23 US US10/784,576 patent/US7202093B2/en active Active
- 2004-02-23 TW TW093104413A patent/TW200502238A/en not_active IP Right Cessation
- 2004-02-23 CA CA2517705A patent/CA2517705C/en not_active Expired - Lifetime
- 2004-02-24 AT AT04004112T patent/ATE464566T1/en not_active IP Right Cessation
- 2004-02-24 DE DE602004026500T patent/DE602004026500D1/en not_active Expired - Lifetime
- 2004-02-24 EP EP04004112A patent/EP1455189B1/en not_active Expired - Lifetime
- 2004-02-24 CN CNB2004100076844A patent/CN100344647C/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874584A (en) * | 1993-04-21 | 1999-02-23 | Eastman Kodak Company | Ion-sensitive compounds |
US6120768A (en) * | 1993-05-17 | 2000-09-19 | Immunomedics, Inc. | Dota-biotin derivatives |
US6143879A (en) * | 1994-01-14 | 2000-11-07 | Regents Of The University Of Minnesota | Nucleotide cleaving agents and method |
US20050038258A1 (en) * | 2001-12-21 | 2005-02-17 | Tohru Koike | Zinc complexes capable of capturing substances having anionic substituents |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060183237A1 (en) * | 2003-03-07 | 2006-08-17 | Kabushiki Kaisha Nard Kenkyusho | Method of measuring the molecular weight of phoshoric acid monoester compound and additive for mass spectrum measurement |
US7476738B2 (en) | 2003-03-07 | 2009-01-13 | Nard Institute Ltd. | Method for identifying molecular weight of a phosphoric acid monoester compound and an additive for mass spectrometry |
US7804592B2 (en) | 2003-10-16 | 2010-09-28 | Nard Institute, Ltd. | Method for measuring a surface plasmon resonance and noble metal compound used for the same |
US20090185181A1 (en) * | 2003-10-24 | 2009-07-23 | Kabushiki Kaisha Nard Kenkyusho | Method for measuring a surface plasmon resonance and noble metal compound used for the same |
US20050269267A1 (en) * | 2004-03-19 | 2005-12-08 | Perkinelmer Las, Inc. | Separations platform based upon electroosmosis-driven planar chromatography |
WO2006014424A2 (en) | 2004-07-06 | 2006-02-09 | Perkinelmer Las, Inc. | Methods and compositions for detecting and isolating phosphorylated molecules using hydrated metal oxides |
US20080064608A1 (en) * | 2004-07-13 | 2008-03-13 | Toyo Boseki Kabushiki Kaisha | Method Of Detecting Phosphorylation By Spr Using Zinc Chelating Reagent |
US20100099120A1 (en) * | 2005-08-09 | 2010-04-22 | Tohru Koike | Method for staining substances having a phosphate group |
US20070187243A1 (en) * | 2005-11-10 | 2007-08-16 | Perkinelmer Life And Analytical Sciences | Planar electrochromatography/thin layer chromatography separations systems |
US20070161030A1 (en) * | 2005-12-08 | 2007-07-12 | Perkinelmer Las, Inc. | Micelle-and microemulsion-assisted planar separations platform for proteomics |
US20070251824A1 (en) * | 2006-01-24 | 2007-11-01 | Perkinelmer Las, Inc. | Multiplexed analyte quantitation by two-dimensional planar electrochromatography |
US20070287161A1 (en) * | 2006-04-28 | 2007-12-13 | Patton Wayne F | Detecting Phospho-Transfer Activity |
US7550271B2 (en) | 2006-04-28 | 2009-06-23 | Perkinelmer Las, Inc. | Detecting phospho-transfer activity |
Also Published As
Publication number | Publication date |
---|---|
EP1455189B1 (en) | 2010-04-14 |
TWI318688B (en) | 2009-12-21 |
EP1455189A1 (en) | 2004-09-08 |
US7202093B2 (en) | 2007-04-10 |
CN100344647C (en) | 2007-10-24 |
DE602004026500D1 (en) | 2010-05-27 |
AU2004218127A1 (en) | 2004-09-16 |
CA2517705C (en) | 2012-01-03 |
ATE464566T1 (en) | 2010-04-15 |
CA2517705A1 (en) | 2004-09-16 |
TW200502238A (en) | 2005-01-16 |
AU2004218127B2 (en) | 2008-12-04 |
WO2004078724A1 (en) | 2004-09-16 |
CN1526724A (en) | 2004-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040198712A1 (en) | Method for labeling phosphorylated peptides, method for selectively adsorbing phosphorylated peptides, complex compounds used in the methods, process for producing the complex compounds, and raw material compounds for the complex compounds | |
KR0133732B1 (en) | Rere earth cryptates, process for their preparation, synthesis intermediates and application as aluorescent traces | |
US4235792A (en) | Immunological materials | |
JP4303595B2 (en) | Zinc complexes capable of trapping substances with anionic substituents | |
EP0403593B1 (en) | Terpyridine derivatives | |
Pettit et al. | Isolation and structure of the marine sponge cell growth inhibitory cyclic peptide phakellistatin 1 | |
CN107056769A (en) | A kind of L cysteines fluorescence probe and preparation method thereof | |
JP2012513973A (en) | Novel fluorescent boron-substituted dipyrromethene and its use in diagnosis | |
PT94226B (en) | PREPARATION PROCEDURE OF 1,2-DIOXETHANES THAT PRODUCE QUIMIOLUMINESCENCE BY DOUBLE ACTIVATION | |
US6080839A (en) | Labeling reactants and their use | |
JP5592057B2 (en) | Labeled transition metal complex | |
CN115322178A (en) | Near-infrared compound, preparation method, butyrylcholinesterase detection kit and application | |
RU2315771C2 (en) | Method for labeling phosphorylated peptides, method for selective adsorption of phosphorylated peptides, chelating compounds used in such methods, method for preparing chelating compounds and parent compounds for preparing chelating compounds | |
CN108794489A (en) | A kind of derivatization reagent and the preparation method and application thereof | |
Hofmann et al. | Syntheses of biotinylated and dethiobiotinylated insulins | |
CN112250700B (en) | BODIPY (boron dipyrromethene) protein misfolding probe Halo-BODIPY as well as preparation method and application thereof | |
CN110873772A (en) | Probe and synthetic method and application thereof | |
US7476738B2 (en) | Method for identifying molecular weight of a phosphoric acid monoester compound and an additive for mass spectrometry | |
US6127529A (en) | Metal-chelating 2,6-disubstituted pyridine compounds and their use | |
EP0298939A1 (en) | Metal-chelating 2,6-disubstituted pyridine compounds and their use | |
Adamczyk et al. | Synthesis of labeled galactosylhydroxylysine | |
CN117924335A (en) | ONOO with endoplasmic reticulum targeting-Fluorescent probe and preparation method and application thereof | |
CN117304246A (en) | Fluorescent probe for detecting glycocholic acid hydrolase as well as preparation method and application thereof | |
JPS58213791A (en) | Substituted theophylline salts | |
Imai et al. | Photoaffinity heterobifunctional crosslinking reagents based on azide-substituted salicylates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KABUSHIKI KAISHA NARD KENKYUSHO, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOIKE, TOHRU;KAWASAKI, AKIHIKO;KOBASHI, TATSUHIRO;AND OTHERS;REEL/FRAME:014677/0753 Effective date: 20040513 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FEPP | Fee payment procedure |
Free format text: 11.5 YR SURCHARGE- LATE PMT W/IN 6 MO, LARGE ENTITY (ORIGINAL EVENT CODE: M1556); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |